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Introduction 
S troke ~uts a large bur~en on ,vestern societie.s. It is the third.lea~g cause of deadl m these countries, and one of dlC major causes of disability.t.3 Stroke tllortality has been declining substantially in developed countries for some 
dccades,I,2,4 Data on stroke incidence arc relatively tare, but existing figures suggest 
that incidence of stroke declined until the 1980s and since then levelled off.l,4 In 
ageing populations the number of affected subjects will grow in the coming years.' 
In the last few decades epidemiologic research identified numerous risk factors 
for stroke," Yet, there arc remaining questions related to the etiology and prevention 
of stroke and some of these are addressed in this thesis. In chapter 2, we study 
whether the classical stroke risk factors as identified in the Framingham risk profile 
still predict accurately the probability of stroke. Chapters 3, 4 and 5 are devoted to 
the associations between hypertension, serum cholesterol, family history of stroke 
and the risk of stroke. In chapters 6, 7, and 8, we investigate the role of dietary anti-
oxidants, aspirin and carotid endarterectomy in the prevention of stroke. Prevention 
measures aim to modify risk factors. It is an interesting question how change in a 
risk factor is related to stroke. In chapter 9, ,vc show our results on the association 
between change in systolic blood pressure and the occurrence of stroke. \,/e use 
this study as an example to call attention to possible bias caused by the prevailing 
method of analysing the relationship bet\veen change in a determinant and the risk 
of disease. 
A major theme in this thesis is the possible prevention of stroke. We should note 
that stroke is not one entity, but a group of disorders. The t\vo major types of stroke, 
ischemic stroke and cerebral hemorrhage are caused by very different padl0mecha-
nisms. Even though their risk factors overlap they should ideally be studied sepa-
rately.' Understanding the etiology of stroke, and finding clues for its prevention, is 
crucial in reducing the burden of stroke. 
The importance of prevention of stroke is further emphasised by the fact, that 
besides supportive care and treatment of acute complications, currently there is no 
treatment for acute ischemic stroke, except for tissue plasminogen activator (tPA) in 
a minority of cases. 5-7 
One of tlle Inost effective strategies on the comtnunity level to prevent stroke 
is to shift the population distribution of major modifiable host and environmental 
risk factors towards lower risk.' Cholesterol lowering might be an option. Clinical 
trials have shown a large benefit in stroke prevention with the use of statins, the 
last generation cholesterol lowering drugs.'·12 On the other hand, observational epi-
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demlological studies provided controversial results. 13·19 In chapter 4, we revisit the 
relation between cholesterol level and the risk of stroke. In chapter 6, we investigate 
whedler dietary antioxidants can prevent stroke. 
The mass strategy of prevention involves many low risk subjects. The safety of 
the interventions is critical for the potential side effects not to exceed the benefits. 
I-Ience, the actual intervention is usually limited to modifying health behaviour or 
environmental factors. Aspirin use and carotid endarterectomy, neither of them free 
from risk of adverse events, are being used in low risk subjects.20-2] W'e evaluate these 
interventions in chapters 7 and 8. 
A complementary approach to a mass prevention strategy is to prevent stroke in 
subjects at high risk for stroke.' The control of hypertension is a simple example of 
this high-risk approach. A problem related to the control of blood pressure is the 
optimal target blood pressure in treated hypertensive subjects.2~27 \'1fe address tills 
issue in chapter 3. 
In chapter 10, the main findings of the work are summarised along with their 
limitations and potential implications. Finally, envisaged directions in epidemiologi-
cal research on the etiology of stroke and in research methods are given. 
REFERENCES 
l. Bonita R. Epidemiology of stroke. Lancet 1992;339:342-347. 
2. Gorelick PB. Stroke prevention. Arch Neural 1995;52:347-355. 
3. Sacco RL, Benjamin EJ, Broderick JP, Dyken 1\.'1, Easton D, Feinberg \"'('1\J, Goldstein 
LB, Gorelick PB, Howard G, Kittner S], Manolio TA, Whisnant ]P, Wolf Pi\. Risk fac-
tors, panel. Stroke 1997;28:1507-1517. 
4. Khaw KT. Epidemiology of strake.] Neurol Neurosurg Psychiatry 1996;61:333-338. 
5. Adams HP, Jr, Brott TG, Crowell Rl'vI, Furlan AJ, Gomez CR, Grotta J, Helgason CM, 
MarIer ]R, \"'('oolson RF, Zivin ]A. Guidelines for the management of patients with 
acute ischemic stroke. A statement for healthcare professionals from a special writing 
group of the Stroke Council, American Heart Association. Stroke 1994;25: 1901-19 t 4. 
6. Adams HP ]r, BrottTG, Furlan AJ, Gomez CR, Grotta], He1gason eM, Kwiatkowski T, 
I.yden PD, _Marler JR, Torner). Guidelines for Thrombolytic Therapy for Acute Stroke: 
A Supplement to the Guidelines for the ~Janagement of Patients \"'(lith Acute Ischemic 
Stroke. A Statement for Healthcare Professionals From a Special \Vriting Group of the 
Stroke Council, American Heart Association Circulation 1996;94:1167-1174. 
7. Alberts 10,'1). tPA in acute ischemic stroke: United States experience and issues for the 
future. Neurology 1998;51 (Suppl 3):S53-S55. 
8. Rose G. The strategy of preventive medicine. Oxford: Oxford University Press, 1992. 
9. Baluw G], Lagaay M, Smelt AHlIl, Westendorp RG]. Stroke, statins, and cholesterol. A 
meta-analysis of randomized, placebo-controlled, double-bind trials with HMG-CoA 
reductase inhibitors. Stroke 1997;28:946-950. 
10. Herbert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering ,vith starin 
drugs, risk of stroke, and total mortality. An overview of randomized trials. ]AMA 
1997;278:313-32l. 
11. Crouse III JR, Byington RP, Boen HM, Put"berg CD. Reductase inhibitor monotherapy 
Introduction 3 
and stroke prevention. Arch Intern j\fed 1997;157:1305-1310. 
12. Crouse III JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and 
stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998;138: 11-24. 
13. Iso H, Jacobs DR, \'(Tentworth D, NealOn JD, Cohen JD, for the 1JRFIT Research 
Group. Serum cholesterol levels and she-year mortality from stroke in 350,977 men 
screened for the multiple risk factor intervention trial. N Eng) Med 1989;320:904-910. 
14. Lindenstrotl1 E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipo-
protein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenha-
gen city heart study. BM] 1994;309: II-IS. 
15. Benfante R, Yano K, H\vang L), Curb D, Kagan A, Ross \'{~ Elevated serum cholesterol 
is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian 
Japanese men. Implication of shared risk. Stroke 1994;25:814-820. 
16. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pres-
sure, cholesterol, and stroke in eastern Asia. Lancet 1998;352:1801-1807. 
17. Prospective studies collaboration. Cholesterol, diastolic blood pressure, and stroke: 
13000 stroke in 450000 people in 45 prospective cohorts. Lancet 1995;346: 1647-1653. 
18. Nakayama T, Date C, Yokoyama T, Yoshiike N, Yamaguchi n1, Tanaka H. A 15.5-year 
follow-up study of stroke in a Japanese provincial city. The Shibata Study. Stroke 1997; 
28:45-52. 
19. Simons LA, .i\kCallum J, Friedlander Y, Simons J. Risk factors for ischemic stroke. 
Dubbo Study of the elderly. Stroke 1998;29: 1341-1346. 
20. Peto R, Gray R, Collins R, \,{'beatley K, Hennekens C, )amrozik K, \'(Tarlow C, Hafner 
B, Thompson E, Norton S, Gilliland .1, Doll R. Randomised trial of prophylactic daily 
aspirin in British male doctors. B11J 1988;296:313-316. 
21. Steering Commitee of the Physicians' Health Study Research Group. Final report 
on the aspirin component of the ongoing Physicians' Health Study. N Engl) 1{ed 
1989;321: 129-135. 
22. Rothwell PM, Slattery .1, \X/arlo\\' CI~ A systematic comparison of the risks of stroke 
and death due to carotid endarterectomy for symptomatic and asymptomatic stenosis. 
Stroke 1996;27:266-269. 
23. Hartmann A, Hupp T, Koch HC, Dollinger P, Stapf C, Schmidt R, Hofmeister C, 
Thompson )L, nIarx P, Mast H. Prospective study on the complication rate of carotid 
surgery. Cerebro"asc Dis 1999;9:152-156. 
24. Coope J. Hypertension: the cause of the J-curve. J Hum Hyperten 1990;4: lA. 
25. Flechter AK, Bulpitt CJ. How far should blood pressure be lowered. N Engl J Med 
1992;326:251-254. 
26. Sleight P. Blood pressure, hearts, and V-shaped curves. Lancet 1988;i:235. 
27. Kaplan N.}curve not burned off by HOT stud),. Lancet 1998;351:1748-1749. 

c h a pte r 2 
How does the 
Framingham stroke risk profile 
perform in Rotterdam? 
Background and purpose - Oil}, ailll JJ!as to e/!{tI/lafe the predirtitfe peiforlJ/rlllce 0/ the Fram-
il/ghalll sflvke lisk profile. 
Methods - This Stllri;' was col/dllcted I/,;tbil/ the Rotterdalll Stllri;~ a p/~specti/le poplilatioll·based 
cohOlf Stllri;' of sllb/ects aged 55 )'etl", or O/Ie!' that sttl/ted ill 1990. Tbis aIM/pis COI/(el'llS 4930 
sf{/yix/s mho }}Iere free from stroke a/ basch'lIe and 01/ l1/JOIJI ]pe bad (oJJJplete iJ!fOrlJltllioll all a/I 
the lisk faclol>' illchlded ill the Fi'tllllillghmil Jisk profile. II/'e assessed lI'hether the profile cor",tl), 
estilllated the IIlIlIIber of strokes that o((IIrred I/,;thil/ three ),etl/" of jollow.,tjJ fll/d whether it col/Id 
disoilJJilltite be/meen high and 1011' lisk SIIlyrets. 
ResuIts - Dlllil/gjollow·ltjJ 141 strokes al/d ImllSi",1 ischelllic al/ades (rIA) oC(llnd, lI'here 
127 w'" experted. The eslilllflied Ih"ej""r lisk of slroke fll/d JIA mllgedjivlII 1.4%0 10 
54.8%. The area flllder the rereilfer operator rharaclcJis/ic C1(rlJe JJ!as 0.72 for stroke and TIA} 
alld 0.75 }}lbm Ollb' stroke 1MS considered as aJl ollfrollle. 
Conclusions - The ['mlllil/ghaill slroke Jisk p/~jile predicls the IIIIIII/"r of slrokes reasollably 
l1'ell, dnd rail be tlHSefll1 tool to disailJJillaie behJlee!J SIIo/crtS u,;th different nsk for sfrok.e. 
R· sk profiles can estimate probability of an event conditionally on specific characteristics of the subject. The tllost well-kno,vn stroke risk profile was ublished from the Framingham Study a decade ago. I The profile included 
the now "classical" stroke risk factors. The function can predict the number of 
strokes in a population and can identify persons at increased risk of stroke. 
The object of our study was to evaluate the performance of the Framingham 
stroke risk profile in the Rotterdam Study. We wanted to see whether the function 
could predict stroke accurately in a different population. Furthermore, we ,vanted to 
assess whether after the advances in the control of hypertension, diabetes, and the 
treatment of cardiovascular diseases in the last decade, the major classical stroke risk 
factors could still largely predict d,e risk of stroke. 
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SUBJECTS AND METHODS 
Study population 
We evaluated the performance of the Framingham stroke risk profile in the Rot-
terdam Study, an ongoing prospective population-based cohort study for which all 
inhabitants aged 55 years or over, living in a suburb of Rotterdam, The Netherlands, 
were invited. The rationale and design of the Rotterdam Study have been described 
elsewhcrc.2 
Baseline data collection was performed between 1990 and 1993. \,hitten informed 
consent and permission to retrieve information from medical records ,vere obtained 
from every participant. The study has been approved by the Medical Ethics Com-
mittee of Erasmus Urtiversity / Academic Hospital Rotterdam. In total 7983 subjects 
participated (response rate 78%). Among them 7603 subjects completed the baseline 
interview and examination, and reported no previous stroke at baseline. Although 
on most variables more than 90 % of data \vas available, we had information on all 
the risk factors included in the Framingham risk profile only in 4930 subjects. Those 
who were not included in this analysis ,vere on average slightly older and more often 
took antihypertensive tnedicatioll, suffered from diabetes mellitus or had coronary 
heart disease. 
Assessment of strokes and transient ischemic attacks (TIA) 
At baseline, information on health status and medical history \vas obtained using 
a computetized questionnaire. Ptevious stroke \vas assessed by direct questioning: 
"Did you ever suffer from a stroke diagnosed by a physician?". If the answer \vas 
'yes" medical records were checked for additional information. A previous stroke 
\vas coded if it was confirmed by tnedical recotds.3 Once subjects enter the Rot-
terdam Study they are continuously monitoted for major events through autotnated 
linkage with the files from the GPs. YI'ith respect to the vital status, information is 
obtained at regular intervals from the nmnicipal authorities in Rotterdam. \Vhen an 
event ot death has been reported, additional information is obtained by interview-
ing the GP and scrutinizing information from hospital discharge recotds in case of 
admittance or referral. Information on all possible strokes was reviewed by a neu-
rologist (PJK) who classified the stroke as definite, probable or possible. The stroke 
was considered definite if the diagnosis was based on both cfinical symptoms and 
neuro-imaging. A probable stroke was considered if no CT or MRI was made but 
if symptoms were highly suggestive for stroke according to the GP or treating neu-
rologist. In case of fatal stroke a cardiac cause of death should have been excluded 
to reach a diagnosis of probable stroke. The stroke was considered possible if the 
treating neurologist diagnosed a 'possible stroke' without neuro-imaging, or if a GP 
recorded a fatal stroke and could not exclude a cardiac cause of death. 
If cr or ]',{RI was performed which showed a haemorrhage or infarct the type of 
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stroke was coded accordingly. In case of no abnormality on CT or MRl the stroke 
\vas classified as ischemic. \X1hcn no CT or J\'iRI was performed, a stroke could 
be coded possible hemorrhagic or ischemic in case of typical complaints or case 
history. A case history of sudden hemiplegia or other focal signs with permanent 
unconsciousness or dcath within hours without neuro-imaging was coded as possi-
ble hemorrhagic stroke. If there was limited impairmcnt, i.e. isolated afasia, isolated 
\veakness of one limb, isolated facial weakncss or isolated hemianopia the stroke 
\vas considered possible ischemic. Furthermore, in case of complete improvement 
\vithin 72 hours 01' documented atrial fibrillation at time of the diagnosis tile stroke 
also was considered possible lschemic. 
Reported TIAs were classified based on all available information as definite, 
probable or possible by study physicians. Only definite and probable TIAs were 
included in the analysis. 
TIllS analysis concerns strokes and TIAs dwt occurred within tiuee years aftcr 
entry in thc study cohort. 
Definition of risk factors included in the risk prome 
Risk factors included in the function were deHned similarly in the Rotterdam Study 
and in the Framingham Study.' W1ith respect to smoking subjects were categorized 
as current smokers and non-smokers, including fonncr smokers. Diabetes mellitus 
was deHned as random or post-load serum glucose level higher than 1 1. 1 mmol/I or 
use of antidiabetic medication.s Sitting blood pressure ,vas measurcd at baseline at 
the right upper arm with a random-zero sphygmomanometer. The average of two 
measurements obtained on one occasion, separated by a count of tile pulse rate, 
was used in this analysis.6 Use of antihypertensive medication was ascertained as 
part of the baseline interview in the subjects' home when participants were asked to 
report and show all vials of medications (either prescription or OTC) that were used 
during the preceding week. Names or brands of drugs were recordcd and classiHed 
according to their corresponding Anatomical-Therapeutical-Chemical-code (ATC-
code). Atrial Hbrillation and left ventricular hypertrophy were assessed by electro-
cardiogram. Definition of cardiovascular disease included history of intermittent 
claudication, angina pectoris, coronary revascularisation procedure, myocardial inf-
arction, and cardiac failure. Prevalence of angina pectoris and intermittent claudica-
tion was assessed by means of a Dutch version of the cardiovascular questionnaire 
of Rose et al.' Heart failure was defined in a two step approach. First, the presence 
of shortness of breath at rest or exertion, ankle edema and crepitations was deter-
mined. If at least two of these were prescnt in combination with evidence of cardiac 
disease) while shortness of breath could not be attributed to chronic obstructive 
pulmonary disease, heart failure was considered present. Secondly, the examining 
physician used standardized questions to verify dlC indication of cardiovascular 
medication with the participant. In case diuretics, glycosides or angiotensine con-
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vetting enzyme inhibitors \vere used, the indication of heart failure 'vas verified 
and classified as no, possible or definite. Only participants with a defmite indica-
tion for heart failure, in whom objective evidence of cardiac disease was found, 
,vere included.s l-listory of myocarcliallnfarction 'vas assessed primarily by direct 
questioning. Self-reported events were confirmed by additional information from 
the general practitioner or cardiologist.9 
Statistical analysis 
\'(/e estimated the risk of stroke and TIA for each subject by imputing the subject 
specific values of the risk factors in the Framingham stroke risk profile. A risk pro-
file that is applicable in practice should estimate the probability of events that are 
comparable in sevetity and future prognosis. Although the original risk function ,vas 
developed to estimate the risk of stroke or TIA, we therefore performed additional 
analyses in \vWeh we only included stroke as event of interest. 
\\Tc first assessed how well the function estimates the number of events that 
occurred within three-years of follow-up. For that ,ve used hvo methods. First, 
we compared the predicted three-year probability of events with the actual threc-
year cumulative incidence of event in deciles of predicted probability. to Second, we 
applied a smoother to obtain a non-parametric estitnate of the "actual probability" 
of stroke in each subject. The "actual probability" was calculated by robust locally 
weighted regression. \'.,Ie used a tricube weight function, and a band,vidth of 0.8. 11 
The relationship between the predicted probability and the "actual probability" is 
presented on a scatterplot. 
Next, to sec how the risk profile could separate subjects who did or did not 
have an event during the follow-up ,ve calculated the area under the receiver operat-
ing characteristic (ROC) curve. i2 A discriminating function yields a wide range of 
predicted risks and assigns higher predicted risks to subjects who ,vill have an event 
than to subjects who ,vill not have an event. The better the discrimination the larger 
the area under the ROC curve is. 
RESULTS 
Baseline characteristics of the study population arc presented in Table 1. They were 
quite comparable to those from the Framingham Study.' Within three years after 
entry 94 strokes and 49 TIAs occurred, resulting in 141 subjects with incident stroke 
or TIA (two subjects had both a TIA and stroke during the follow-up). 
Table 2 shows the three-year cumulative incidence of events in deciles of the 
estimated probability and the numbers of observed and expected cases. The total 
number of expected cases was 127) the estimated three-yenr risk ranged ftom 1.4%0 
to 54.8%. Ninety percent of subjects had an estimated three-year risk of stroke or 
TIA smaller than 5.3%. From d,e table it can be seen d,at the function estimates 
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Risk factor Men Women 
-,,----'''''"--
Age (year) 67.0 (7.1) 67.9 (7.7) 
Systolic blood pressure (mmHg) 138.4 (21.7) 138.8 (22.5) 
Antihypertensive therapy 29.7 34.1 
Diabetes mellitus 10.8 10.4 
Smoking 28.5 19.3 
Cardiovascular disease * 24.7 16.0 
Atria) fibrillation 2.4 1.6 
left ventricular hypertrophy 4.9 4.0 
Values are means (SO) or percentages. 
* Cardiovascular disease: history of intermittent claudication, angina pectoris, coronary 
revascularisation procedure, myocardial infraction, or cardiac failure. 
Observed number of Three~year cumulative 
Expected events incidence (0/0) Decile of estimated "''''-''''--
three~year risk (%) number of Stroke and Stroke and 
events definite! Stroke definite! Stroke 
prob. TIAs prob. TlAs 
" ---,,-'"--,,-"'-"'-----,,--
0.0 - 0.52 2 6 2 1.22 0.41 
0.53 - 0.76 3 4 2 0.81 0.41 
0.77 - 1.00 4 6 3 1.22 0.61 
1.01 - 1.28 6 7 3 1.42 0.61 
1.29 - 1.60 7 4 3 0.81 0.61 
1.61 - 2.01 9 7 3 1.42 0.61 
2.02 - 2.57 11 13 11 2.64 2.23 
2.58 - 3.45 15 22 17 4.46 3.45 
3.46 - 5.27 21 33 24 6.69 4.87 
5.28 - 49 39 26 7.91 5.27 
prob.: probable; TIA: transient ischemic attack. 
the risk of stroke in tnost categories reasonably well. Figure 1 shows the scatter 
plot of the predicted three-year probability of stroke and 111\ and the "actual prob-
ability" of events. It shows that in the range of probability of 0.01-0.05, where the 
vast majority of subjects belong, the function sotnewhat underestimates the actual 
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Figure 1 
Scatterplot of the pre-
dicted three-year prob-
ability of event and of 
the actual probability 
of event (logarithmic 
scales). 
Figure 2 
ROC curve of the Fram-
ingham stroke risk pro-
file. 
probability of stroke and TIA. On the other hand, as expected, the function slightly 
oyerestimates the probability of eyent if only stroke is considered. 
Figure 2 presents dle ROC curve of the function. The area under the curve 
was 0.72 (95% confidence interval 0.68-0.76) and 0.75 (95% confidence interval 
0.71-0.79) for stroke or TIA, and for stroke only, respectively. This shows that the 
function discriminates equally regardless whether only stroke or stroke and TIA arc 
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CuHff point Sensitivity Specifjcity 
0.026 70 71 
'0.024' 75 68 
0.022 80 65 
0;017 85 54 
0.012 90 37 
0.008 95. 22. 
,. Only stroke was considered as an event of interest. 
considered as outcome. We additionally tabulated the sensitivity and specificity of 
the function corresponding to different cut-off points of the estimated three-year 
risk (Table 3). Only stroke was considered here as event of interest. The table shows 
that, for example, choosing an estimated risk of 2.4% Or higher for identifying high 
risk subjects would mean that 75% of the future cases would be correctly identified 
whereas 32% of subjects who would not have a stroke within three years would be 
labeled as high risk. 
DISCUSSION 
We evaluated ti,e performance of ti,e Framingham stroke risk proftle. We found 
that the function estimates the three-year risk of stroke reasonably well. The total 
number of expected events is close to the observed number, and the prevalence of 
ti,e event is fairly well predicted in most categories of ti,e estimated risk. Our results 
show that major classical stroke risk factors still largely predict the risk of stroke. 
The estimated probability had a wide range, and the function could discriminate 
b.etween subj~cts withdifferent.risk for strllke. 
We evaluated the first ver.sion of the Framingham stroke risk proftle. 1 A slightly 
modified version of 'ti,e original function wa's published',later, but witilOut all the 
necessary deatil t6 eriable validation in another'datas'e't. 13 
Out study has some limitations. The follow~up was only three years. Also, there 
was a rela~~ely large vroportion of subjects that we could not include in ti,e analysis 
be~aus~.~f:mis~ing da.ta for Qne or morc of the.cqvariates in,the model. N,cverthe-
less; in p1"actic~ ~he function can be used only in subjects with information on all 
tI,eir· risk factors. 
Since the main uSe of a risk proftle is t6 classify subjects into gr()ups with differ-
, entprognosis the 'most important feature of a risk proftle from ti,e practical point 

I~ 
3 
J -shaped relation between 
blood pressure and stroke 
in treated hypertensives 
The objertit1e of this stlldy }pas to illl!estigate the relatiollship betweell h)p8ltellsioll alld fisk q( 
strok~ ill the elderlY. Th, Stlldy """ mnied Ollt withill the ji'tllltelpork of the Rotterdalll Stllr/;, a 
pmspectil!e poplllatioll-based (Ohol1 Stlldy. The fisk of ji,Jt-elfer stmke Ipas assoriated with I;yper-
tellsiOIl (relatill' lisk 1.6, 95% (Olifidelice illterml 1.2-2.0), alld with isolaled systolic iop8ltellSioli 
(ldatil!e lisk 1.7, 95% COIifidelire illlel'lla/I.I-2.6). We folllid a {OlililiIiOIlS illmas, ill slroke 
incidence J}Jith lilCl"fasillg blood pressllre liJ 1I01l-b"f(/ted silo/eels. In treated silo/eels JJJe follnd (/ 
J-shaped Idatioll behnell blood presslllw alld Ihe lisk of slroke. III Ihe 10ll'esl ralegOlJ of diaslolic 
blood pressllre Ih, illmase of slrok~ lisk I/laS slalislimllY sigllificalll rOlllpared 10 the refomlCe 
rategOlJ. H)p8ltellSioli alld isolated systolir ioP8ltelisioli (/It strollg lisk fartOl'-for Stl~ke ill the 
elderly. The illmased stmke lisk ill the lowest stmta of blood pmsllre ill treated I;ypel1ellsil!e 
patiellts lIIay illdirate Ihallhe IhempeJIlic gOllI ''lhe 1000'er Ihe belieI''' is 1101 the oplilllal stmtegy ill 
Ihe elderly. 
H ypertension is a well-established risk factor for stroke in elderly people. I.6 There is increasing evidence showing the importance of isolated systolic hypertension in the etiology of stroke) 1,7-13 and now it is recognized as an 
independent risk factor for cardiovascular morbidity and 111ortality.I4-16 The results 
of clinical trials indicated that treatment of hypertension could reduce the risk of 
stroke considerably, also in the elderlyY-21 Although two clinical trials have investi-
gated the optimal target blood pressure level in treated hypertensive patients, it is still 
a question v,rhether the risk of stroke continues to decrease the further the blood 
pressure is reduced in hypertensive patients,22-Z4 
We carried out a prospective cohort study in an elderly Dutch population to 
investigate the relationship between hypertension and stroke in the elderly. Further-
more, we studied the relationship between blood pressure level and the risk of stroke 
separately in subjects using and not using antihypertensive medication. 
15 
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METHODS 
Study population 
This study was conducted in the framework of the Rotterdam Study, an ongoing 
prospective population-based cohort study for which all inhabitants aged 55 years or 
over, living in the suburb of Rotterdam, The Netherlands, were invited. The ration-
ale and design of the Rotterdam Study have been described elsewhere.25 
Baseline data collection was performed between 1990 and 1993. Written informed 
consent and permission to retrieve information from medical records were obtained 
from every participant. The study has been approved by the Medical Ethics Com-
mittee of the University Hospital of Rotterdam. In total 7983 subjects participated 
(response rate 78%). Among them 7725 subjects reported no previous stroke at 
baseline, of them 6927 visited dlC research center where their blood pressure was 
measured. Among them the distribution of age and gender, and the frequency of 
diabetes, angina, and of previous tnyocarcUal infarction was sinillar to the rest of the 
cohort. 
Outcome 
Once subjects enter the study they are continuously monitored and followed through 
linkage with automated medical records of the general practitioners working in 
the study area. Furthermore, bimonthly updates from the municipality records arc 
obtained. When an event or death is reported, additional information is obtained by 
interviewing the general practitioner and scrutinizing the medical files or hospital 
discharge records in case of admittance or referral. TIllS analysis concerns events 
that occurred till December 31, 1996. Complete follow-up was available for 6287 
subjects (91 %). 
All suspected stroke cases reported were reviewed by a neurologist (P. J.K.), who 
classified them as definite, probable or possible strokes or as non-stroke events/6 
and determined stroke subtypes. 
Determinant 
Sitting blood pressure was measured at baseline at the right upper arm with a ran-
dom-zero sphygmomanometer. The average of two measurements obtained on one 
occasion, separated by a count of the pulse rate, was used in this analysis.27 Use 
of medication was ascertained as part of the baseline intervie,v in subjects' home. 
Hypertension was defined as systolic blood pressure equal to or higher than 160 
mmHg, or diastolic blood pressure equal to or higher than 95 mmHg, or usc of 
antihypertensive medicationP Isolated systolic hypertension was defined as systolic 
blood pressure equal to or higher than 160 mmHg, diastolic blood pressure lower 
than 90 mmHg and not being treated for hypertension. 
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Potential confounders 
\X'ith respect to smoking behavior subjects were categorized as current or former 
smokers, and those who never smoked. Diabetes mellitus was deHned as random or 
post-load serum glucose level higher than Il.lmmol/l or use of antidiabetic medi-
cation.28 Prevalence of angina pectoris and claudication was assessed by means of 
a Dutch version of the cardiovascular questionnaire of Rose et aI,29 Ankle-to-arm 
systolic blood pressure index was defined as the ratio of the systolic blood pres-
sure measured at the arm and at the ankle at the same side.30 A history of transient 
ischemic attack (11A) was assessed on the basis of answers to the questions about 
experiencing a shon period with disturbances of sensibility, strength, speech, or 
vision. If a positive answer was given, more detailed information was obtained, and 
the event was categorized as typical TIA, atypical TIA or no TIA, by a neurologist 
(P]K).31 History of stroke or myocardial infarction was assessed primarily by direct 
questioning. Self-reported events \vere confirmed by additional information from 
the general practitioner, cardiologist or neurologist.32,33 
Statistical analysis 
All first-ever strokes were included in the analysis. Relative risks and 95% confidence 
intervals were estimated through Cox-regression. 
\Y/e compared dle risk of stroke between hypertensive and normotensive subjects 
and bet\veen subjects with isolated systolic hypertension and non-treated subjects 
having systolic blood pressure lower than 160 mmHg and diastolic blood pressure 
lower than 90 mmHg. The risk estimates were adjusted for age, gender, smoking 
habits and diabetes mellitus. We refrained from adjustment for cardiovascular dis-
eases because they were considered to be intermediate steps in the disease process 
or indicators of severe hypertension. 
We also investigated the effect of blood pressure level on stroke risk among 
treated and non-treated subjects. To reduce confounding caused by severe athero-
sclerosis associated with high systolic and low diastolic blood pressure these analy-
ses were adjusted for age, gender, smoking habits, diabetes mellitus, ankle-to-arm 
index, minor vascular events (intennittent claudication, angina pectoris, history of 
coronary revascularisation procedure), myocardial infarction, atrial Hbrillation, typi-
cal and atypical TIA. 
Missing data of potential confounders were handled by the indicator method." 
On all confounders more than 90% of data was available. 
RESULTS 
Table 1 shows the baseline characteristics of the study population. The study 
cohort was followed for an average of 4.7 years. Among them 277 Hrst-cver strokes 
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, Characteristic 
Age (year) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Serum cholesterol (mmol/I) 
Men 
Current smoker 
Former smoker 
Diabetes mellitus 
Atrial fibrillation 
Intermittent claudication 
Angina pectoris 
Coronary revascularization 
History of myocardial infarction 
History of typical TIA 
. History of atypical TIA 
Values are means (SD) or percentages. 
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.. 
~ 
. " c ~ ~ 
" " ° 
c 
'§ .. a> ~ c 
° 
.a ... 
" ~ E ° ~ 
" " ~ 0 z1;; fl. 
Hypertension 
no 3936 130 
yes 2351 147 
Isolated systolic 
hypertension 
·no 3241 92 
yes 345 25 
CI: confidence interval . 
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Hypertensive subjects Normotensive subjects 
(n = 2351) (n = 3936) 
71.5 (8.9) 68.4 (8.9) 
156.7 (22.4) 130.5 (16.1) 
79.9 (12.4) 70.4 (9.8) 
6.7(1.2) 6.6(1.2) 
34.3 42.4 
18.4 25.2 
40.4 41.9 
16.4 7.7 
3.2 2.4 
2.3 1.2 
9.7 5.3 
3.8 2.6 
16.1 10.8 
1.9 1.3 
2.5 1.4 
Relative risk (95% CI) 
c 
• 
° 
.., ~
f? c - c 
., 
" 
.., " " .. c. .. " ~ g E 
" 1;; C1 " 
.- ~ 
'0 f? .t:: (f) " .. .., :g.=. eo tV !O' a.. C ~ 0 " «0" «~ (J) ~ >- ~C1
7.0 1.00 (reference) 1.00 (reference) 
13.8 1.59 (1.25-2.02) 1.58 (1.24-2.01) 
5.9 1.00 (reference) 1.00 (reference) 
15.8 1.80 (1.15-2.81) 1.69 (1.08-2.64) 
----,---
.. : adjusted for smoking habit and diabetes mellitus. 
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occurred. Of these strokes 7.2% were hemorrhagic, 73.7% ischemic, and 19.1% 
could not be specified. 
A statistically significant association between hypertension, isolated systolic 
hypertension and the risk of first-ever stroke was observed (Table 2). 
No anllhypartanslve drug use 
4 
~ 2 f • > ~11·  
0.6 
0.26 "--_____________ _ 
<130 130-149 160-169 >169 
Systolic blood pressure ImmHg) 
Figure 1 
Antihypertensive drug use 
4 
~2 ~+ ~ E 1 +--1----'· 
~ 
0.6 
0.26 "--_____________ _ 
< 130 130-149 160·169 > 169 
Systolic blood pressure ImmHgJ 
Association between systolic blood pressure and risk of first-ever stroke, according 
to antihypertensive treatment. Reference category Is the second lowest category of 
systolic blood pressure. Values are plotted on logarithmic scale. 
* Adjusted for age, gender, smoking habit, diabetes mellitus, ankle-to-arm index, 
minor vascular events (intermittent claudication, angina pectoris, history of coronary 
revascularisation procedure), myocardial infarction, atrial fibrillation, typical and 
atypical TIA. 
No anllhypertenslve drug use 
~ 4 t I ~ 2 
~ :; t .. ~ 1 __ 10' ________ _ 
0.6"--_____________ _ 
< 66 66-74 76-84 > 84 
Diastolic blood pressure ImmHg) 
Figur.2 
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. 
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~ 
2 
• 
Antihypertensive drug un 
j . 
~ 1,-~--- ___ +-__ -L ___ 
0.6"--_____________ _ 
< 66 65-74 76-84 > 84 
Diastolic blood pressure ImmHgJ 
Association between diastolic blood pressure and risk of first-ever stroke, according 
to antihypertensive treatment. Reference category is the second lowest category of 
diastolic blood pressure. Values are plotted on logarithmic scale. 
* Adjusted for age, gender, smoking habit, diabetes mellitus, ankle-to-arm index, 
minor vascular events (intermittent claudication, angina pectoris, history of coronary 
revascularisation procedureL myocardial infarction, atrial fibrillation, typical and 
atypical TIA. 
20 Chapter 3 
In subjects who did not: use antihypertensive medication a continuous increase in 
risk was observed with increasing level of both systolic (Figure I) and diastolic 
blood pressure (Figure 2). In patients who used antihypertensive drugs a J-shaped 
relation was found between both systolic and diastolic blood pressure and the inci-
dence of stroke. For diastolic blood pressure the increase of the risk in the lowest 
category as compared to the reference was statistically significant. 
To examine the possibility that the J-curve that we found ,vas due to the excess 
amount of subjects with isolated systolic hypertension among those with the lowest 
diastolic blood pressure, we excluded subjects with isolated systolic hypertension. 
This did not materially change our results. We carried out analysis with adjustment 
for systolic blood pressure, and also with exclusion of subjects with history of myo-
cardial infarction or coronary revascularisation procedure. This did not change the 
shape of the relationship between diastolic blood pressure and stroke. 
DISCUSSION 
W/e found associations of hypertension, and isolated systolic hypertension with the 
occurrence of stroke. TillS is the first study clearly showing a J -shaped relation 
between diastolic blood pressure and the incidence of stroke in treated hypertensive 
subjects. 
Regarding the relation belween hypertension, isolated systolic hypertension and 
risk of stroke in the elderly, our results are in accordance with the results of other 
epidemiological studies. l-13 
However, we may have slightly underestimated the risk of stroke in hypertensive 
subjects, since some subjects could have started taking antihypertensive medication 
after baseline and tlllS could have decreased tl,eir risk. Nevertheless, we tllink that 
tlllS has not greatly influenced our major findings. 
Most of tl,e studies published on the association of blood pressure and tl,e 
risk of stroke indicate a continuous increase in risk <?ver the whole range of blood 
pressure,35 altIlough fe\v could evaluate the relationship between blood pressure 
and stroke risk in elderly subjects \vith very low blood pressure,J6 Nonetheless, in a 
case-control study an increased risk of stroke was reported in treated hypertensive 
patients with low diastolic or systolic blood pressure." In tlle Cardiovascular Healtll 
Study, a cohort study similar to tl,e Rotterdam Study, the risk of stroke tended to 
increase in treated hypertensive patients \vhose systolic blood pressure was lower 
than 128 mmHg.' In a cohort of Norwegian elderly subjects an upturn of stroke 
mortality was seen at low diastolic blood pressure,3B AltIlough none of these results 
were statistically significant tIley are in accord with our finding, and they suggest 
that the optimal target level of blood pressure in elderly hypertensive patients might 
be higher than the conventional "normal" level. Sitnilar results have been repeat-
edly reported on the relation between blood pressure and myocardial infarction>w,4o 
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In this case, however, the relationship does not seem to be restricted to treated 
subjects.41 + 44 
Two intervention trials have addressed the question of the optimal blood pres-
sure reduction. In the Behandla Blodtryck Battre trial there was no difference in 
cardiovascular mortality and morbidity between subjects with essential hypertension 
who had their diasto!ic blood pressure lowered below 80 mmHg or between 90-100 
mmHg. However, only few cases of strokes and myocardial infarctions occurred 
during the follow-up, thus the power of this study is limited." The Hypertensio,\' 
Optimal Treatment trial investigated the relation between three levels of t.~rget 
diastolic blood pressure (:'090, :'085 or =80 mmHg) and the incidence of cardiovas-
cular morbidity and mortality in hypertensive patients. For stroke the lowest risk was 
in the group with diastolic blood pressure below 80 mmHg and an average systolic 
blood pressure at 142.2 rrunHg. However, the study did not have enough power 
to study the relationship 'mder 130 mmHg systolic blood pressure and 75 mmHg 
diastolic blood pressure thus it neither confirmed nor excluded the possibility of a 
J-shaped relation." 
One explanation for the J curve could be that the progression of atherosclero-
sis causes a wide pulse pressure through vessel wall stiffening accompanied by low 
diastolic pressure, and that is why low diastolic blood pressure is associated with 
excess cardiovascular nlorbidity.4,S.47 Our data suggest that advanced atherosclerosis 
can not, or ouly partly explain tl,e phenomenon, since we found tl,e J-shaped rela-
tionship after adjusttnent for major cardiovascular risk factors and cardiovascular 
diseases, and after exclusion of subjects with nlyocardial infarction and coronaty 
revascularisation procedure. 
Excess amount of subjects having isolated systolic hypertension among those 
with tl,e lowest diastolic blood pressure could be another plausible explana60n for 
the] -curve we found. However, tlus was not the case in our study. The relationslup 
between diastolic blood pressure and stroke remained essentially tl,e same after 
adjustment for systolic blood pressure or exclusion of subjects Witll isolated systolic 
hypertension. 
It is likely that anotl,er mechanism can playa role in tl,e increased stroke risk 
among treated hypertensive subjects witll very low blood pressure also. Chronic 
hypertension slufts the lower and upper blood pressure limits of cerebral blood flow 
autoregulation towards higher pressure." This adaptive change protects the brain 
against high intravascular pressure on the one hand, but at the same time tnakes the 
brain more susceptible to ischenlia at low blood pressure. In eldetly subjects tlus 
change may be irreversible.49 
Witllln tl,e group of treated subjects we could not investigate to what extent low 
blood pressure was due to the antihypertensive treatment itself. Nevertlleless, low 
blood pressure did not increase tl,e risk of stroke in non-treated subjects. 
The risk of stroke in elderly hypertensives seems lowest at blood pressure levels 
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around 140/80 mmHg. In the face of current evidence cautious reduction of blood 
pressure in elderly individual.s is rec01nmended. 
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Cholesterol and risk of stroke. 
There is no paradox 
Background - Whelher high SeIYlIJJ (holeslerol is assorialed wilh slroke is slill fOlllro/imial. The 
oly'ectiJJe if this stfl(fy )pas 10 Iim8stigale tbe relatioNship /Jehl'eell serll!JJ cholesterol tllld Of(f(I'I'eI/rc 
of isch,,"ic slrok£. 
Methods and Results - This sll/(iy was fOlldllcled lPilhill Ihe Rotterdalll SllIdy, all ollgoillg 
prospeelil!e pop"lalioll-based coholt silldy of pmom aged 55 )'MI)' or 0/1"; litJillg ill a sllbll1b of 
Rotterdalll, The Nelhedallds. Baselille data fOlleeliolllPlls peifonllCd belweell 1990 IIIld 1993. All 
slilyecls wm (OlllillIlOIlSIy IIIOlliIOl,d alldfollowed IhlVll[,h lillkage with alliomaled ""diml mords 
of Ihe gmeral pracliliollC/J ,,'orkill[, ill Ihe sllId), lII'a. This {/I/t1lysis COII(ems 6659 slIb/eels Illho 
Illm ji.e jiVlII siroke al base/im, had Iheir btlse/ille SeIYlIlI choleslClvlle/fel assessed, alld did 1101 
lise h'pid lowetill[, dnl[,s al base/ille. The llleall JoIIOlP-lIj> lillie lPas 4.5 ),eal'S alld 273 jim ischelllic 
slrokes o((fIlTed dll1ill[, Ihe Jo"olP-llj>. High SeIYlIlI choleslerollwe/ Sigllijifflllily illmased Ihe lisk of 
ischellJic stroke til silo/eels JJlho were free frolJ/ rardiO/JasCIIlal'diseases alld diabetes /}Jellillls (highest 
qllt111i1e /ImllS lowesl qllt111ile, Idalitle lisk 2.3,. 95% (Olr/idellce illler/ltlll.2-4.4). Sem"llolal 
(holeSlerol/ high dellsily lipoproleiJl (holeslerol ralio IMS assorialed with Ihe tisk of slroke IICilher 
iJllhe lo!tll SII/(!ypop"lalioJl Jlor iJl sllb/eelS Fee jiVlII (ardiovasCIIlar diseases alld diabetes me/lillls. 
Conclusions - 1/7e Jolllld CI!ideJlee Ihal high semlll (holeslerollewl comideraN), illcreases Ihe tisk 
of ischemic slroke. 
Clinical trials with HMG-CoA reductase inhibitors have shown a 30 percent reduction in the risk of stroke by these drugs.1-4 However, observational studies have provided controversial results about the relationship benveen 
serum cholesterol and the risk of stroke. Some confirm that cholesterol .increases 
d,e risk of stroke,'·8 the bulk of the evidence points to no relation.'·!! Although 
statins may have other beneficial effects than cholesterol lowering which may pardy 
explain their effect,!2 dus apparent paradox needs further explanation. 
In this paper we present results on the relationslup between serum total choles-
terol, serum total cholesterol/high density lipoprotein cholesterol ratio and the risk 
of ischemic stroke from a prospective population based cohort study and reconsider 
previous results. 
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METHODS 
Study population 
Tlus study was conducted within the Rotterdam Study, an ongoing prospective pop-
ulation-based cohort study for which all inhabitants aged 55 years or over, living in 
a suburb of Rotterdam, The Netherlands, were invited. The rationale and design of 
the Rotterdam Study have been described elsewhere. 13 
Baseline data collection was performed between 1990 and 1993. Written informed 
consent and permission to retrieve information from medical records were obtained 
from every participant. The study has been approved by the Medical Ethics Com-
nuttee of the University Hospital of Rotterdam. In total 7983 subjects participated 
(response rate 78%). Among them 7603 subjects completed the baseline interview 
and examination, and reported no previous stroke at baseline. We excluded 164 sub-
jects who used lipid lowering drugs at baseline. From the remaining cohort serum 
cholesterol was measured in 6659 subjects and these were included in this study. 
Outcome 
Once subjects enter the study they are continuously monitored and followed through 
linkage with automated medical records of the general practitioners working in 
the study area. Furthermore, bimonthly updates from the municipality records are 
obtained. When an event or death is reported, additional information is obtained by 
interviewing the general practitioner and scrutinizing the medical mes or hospital 
discharge records in case of admittance Of referral. This analysis concerns events 
that occurred till December 31, 1996. 
All suspected stroke cases reported were reviewed by a neurologist (PJK), who 
classified them as definite, probable or possible strokes or as non-stroke events, and 
determined stroke subtypes." Hemorrhagic strokes were excluded from d,e analysis. 
Unspecified strokes wcre included in the analysis, because, since their vast majority 
is ischemic, including them causes less misclassification than excluding them. Nev-
ertheless, to estimate the amount: of possible bias, separate analyses were carried out 
with exclusion of unspecified strokes. 
Determinant 
A vein puncture was performed using a 21 gauge Butterfly needle with tube (Sur flo 
winged infusion set, Terumo, Belgium) and non-fasting blood was taken. A detailed 
description of d,e blood sampling has been given elsewhere." Briefly, samples were 
taken with minimal stasis, put on ice immediately after sampling, processed within 
30 nunutes and snap frozen and stored in liquid nitrogen (_800 Celsius), and later 
stored at _200 Celsius for prolonged storage. Serum total cholesterol was deter-
mined using an automated enzymatic procedure.16 Similarly, lugh density lipoprotein 
(HDL) cholesterol was measUl'ed after precipitation of the non-HDL fraction with 
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phosphotungstate-magnesium. 
Potential confounders 
\\lith respect to smoking subjects were categorized as current or former smokers, 
and those \vho never smoked. Diabetes tnellitus was defined .as random or post-
load serum glucose level higher than ILl mmol/I or use of antidiabetic medica-
tion. 17 Hypertension was defined as systolic blood pressure equal to or higher than 
160 mmHg, or diastolic blood pressure equal to or higher than 95 mmHg, or use 
of antihypertensive medication.18 Prevalence of angina pectoris was assessed by 
means of a Dutch version of the cardiovascular questionnaire of Rose et al. 19 His-
tory of stroke or myocardial infarction was assessed primarily by direct question-
ing. Self-reported events were confirmed by additional information from the general 
practitioner, cardiologist or neurologist.2o•21 A history of transient ischemic attack 
(TIA) was assessed on the basis of answers to the questions about experiencing a 
short period with dishubances of sensibility, strength, speech, or vision. If a posi-
tive answer was given, more detailed information was obtained, and the event was 
categorized as typical 11A, atypical TLA or no TIA, by a neurologist (PJK).22 
Statistical analysis 
All first-ever non-hemorrhagic strokes were i.ncluded in the analysis. Serum choles-
terollevel \vas categorized into quartiles. Relative risks and 95% confidence intervals 
were estimated through Cox-regression. 
Subjects with high cholesterol are likely to start using lipid lowering drugs and 
consequently reduce their serum cholesterol level. To verify tIus assumption \ve 
checked the proportion of subjects who started using lipid lowering drugs after the 
baseline examination in the different categories of serum cholesterol. Furthermore, 
we shldied \vhether the proportion of drug users \vas different in subjects who suf-
fered from cardiovascular diseases. \,Te could carry out these analysis because since 
January 1, 1991 the database of the Rotterdam Study was linked to an automated 
pharmacy database which registers all prescription forms filled in at the pharmacies 
of the study area by subjects belonging to the Rotterdam Study cohort. 
\'Ife performed additional analyses after exclusion of subjects with history of 
coronary revascularisation procedure, myocardial infarction or transient ischemic 
attack or \vith presence of diabetes mellitus, angina pectoris or atrial fibrillation on 
ECG. 
To see whether the effect of cholesterol was modified by age, the association was 
analyzed separately in strata up to and above age 70 years. 
Missing data of potential confounders were handled by the indicator method." 
On confounders more than 90% of data was available except diabetes nlellihls 
(84%). 
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RESULTS 
Table 1 shows the baseline characteristics of the study population. The study 
cohort was followed for an average of 4.5 years. Among them 293 first-ever strokes 
occurred. Of these strokes 6.8% were hemorrhagic (90% confirmed by brain scan), 
72% ischemic (61% were confirmed by brain scan), and 21.2% could not be speci-
fied. Hemorrhagic strokes were excluded from the analysis. 
Serum total cholesterol \vas not associated with the risk of first-ever stroke in the 
total study population (fable 2). On the other hand, in subjects free from diabetes 
mellitus and cardiovascular diseases high cholesterol level statistically significantly 
Subjects without Subjects with 
Characteristic ischemic stroke ischemic stroke 
(n = 6386) (n = 273) 
--'"---------------
Age (year) 
Serum cholesterol (mmolll) 
Men 
Current smoker 
Former smoker 
Hypertension 
Diabetes mellitus 
Angina pectoris 
History of myocardial infarction 
Values are means (SD) or percentages. 
Serum 
cholesterol 
(mmolll) 
<5.9 
5.9-6.6 
6.7-7.4 
>7.4 
Subjects Number 
at risk of strokes 
1569 
1992 
1370 
1708 
80 
87 
42 
64 
69.1 (9.0) 77.6 (9.4) 
6.6 (1.2) 6.4 (1.2) 
40.0 35.2 
22.8 25.5 
41.9 32.5 
33.2 52.3 
11.1 22.8 
6.4 9.9 
11.4 22.5 
Relative risk * 
In the total study 
population 
1.0 (reference) 
1.0 (0.7,1.4) 
0.8 (0.5, 1.2) 
1.0 (0.7, 1.5) 
In subjects free from 
diabetes mellitus and 
cardiovascular 
diseases 
1.0 (reference) 
1.7 (0.9, 3.3) 
1.5 (0.7, 3.1) 
2.3 (1.2, 4.4) 
,. Adjusted for age, gender, smoking habit, hypertension, diabetes mellitus, angina pectoris, 
coronary ravascularisation procedure, previous myocardial infarction, atrial fibrillation, 
previous TIA. 
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Cumulative incidence of ischemic stroke in men free from diabetes mellitus and cardiovascular diseases with low and high 
serum cholesterol levels according to two age strata. 
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increased the risk of stroke (fable 2). Exclusion of unspecified strokes did not 
materially change the result. 
Serum total eholesterol/ high density lipoprotein cholesterol ratio was associated 
with the risk of stroke neither in the total study population nor in subjects free from 
cardiovascular diseases and diabetes mellitus. 
Those \vho suffered fr01ll cardiovascular diseases, including angina pectoris, atrial 
fibrillation, coronary rcvascularisation procedure, myocardial infarction and transient 
ischemic attack were more likely to start using lipid lowering drugs after baseline 
examination than those \vho were free from these dis cases (15 versus 10 percent). 
Similarly, of those who had high cholesterol level at baseline (upper quartile) 25% 
started lipid lowering drugs thereafter as opposed to only 2% of subjects in the 
lower quartile. Nevertheless, exclusion of subjects \vho started using lipid lowering 
drugs after baseline examination did not materially change our results. 
The relative risk of stroke was somewhat higher in younger subjects than in the 
elderly, relative risk in the highest quartiles 2.5 (95% confidence interval 0.8, 7.9) and 
2.0 (95% confidence interval 0.9, 4.5) This was due to the higher background risk in 
older subjects. As an illustration for the phenomenon we plotted the absolute risk 
of stroke for men according to two age strata. It is apparent that high cholesterol 
increases the risk of stroke considerably also in the older age group (Figure 1). 
DISCUSSION 
We found that high serum cholesterol level increased the risk of ischemic stroke in 
subjects free from diabetes mellitus and cardiovascular diseases at baseline. 
In our study, like in almost all others, serum cholesterol level was determined 
only once. Due to regression dilution bias this may dilute the association between 
typical cholesterol level and the risk of stroke.24~5 Furthermore, subjects with high 
cholesterol were more likely to start using lipid lowering drugs and probably to 
change their diet after baseline examination, and this could also result in an under-
estimation of their risk of stroke. Nevertheless, exclusion of subjects who started 
using lipid lowering drugs aftet baseline did not materially change our results. 
Current evidence about the relationship between cholesterol and the risk of 
stroke is inconsistent. Several methodological difficulties should be addressed regard-
ing available results. 
Since stroke may alter serum lipid levels,26,21 case-control studies may lead to biased 
results if lipid levels are measured immediately after stroke. In a case-control study 
in which serum cholesterol levels were determined three months after stroke, a 
statistically significant relationship was found behveen serum cholesterol level and 
having experienced an ischemic stroke.28 However, this still docs not tell whether 
increased levels indeed increase the risk. The cohort studies in which cholesterol 
level was assessed before stroke yielded controversial results.5-11 In a meta-analysis 
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of 45 cohorts, no relationship was found between serum cholesterol and the risk 
of stroke.' On the other hand, high serum cholesterol increased the risk of death 
from non-hemorrhagic stroke among subjects screened for the Multiple Risk Factor 
Intervention Tria1.s A recent meta-analysis of Asian cohorts also sho\ved a positive 
association bet\veen cholesterol and ischemic stroke,1O and in a Danish study the risk 
of stroke was statistically significantly higher in subjects with cholesterol level above 
8 m11101/1 than in subjects with cholesterol level under 5 mmol/!.6 
Several factors may explain the controversy. In many studies - also among those 
involved in the meta-analysis of the Prospective Studies Collaboration9 - stroke 
subtypes were not analyzed separately. Since low cholesterol level is associated with 
hemorrhagic stroke,29,30 studies in which any stroke is the outcome are unlikely to 
demonstrate increased stroke risk \vith high cholesterol level, and this is even tnore 
unlikely when fatal stroke is considered as outcome, since the case-fatality rate of 
hemorrhagic strokes is highet}1-36 thus their proportion is higher among fatal strokes 
than among any strokes. 
In the meta-analysis of the Prospective Studies Collaboration all cholesterol 
values above 6.38 mmol/l were lumped, and this may partIy explain why no associa-
tion was found, since tIus could obscure the possible effect of very high cholesterol 
levels.9,37 
Our study points to yet anotI,er explanation, related to possible confounding 
effects of otIler cardiovascular patIlOlogy. In our study serum total cholesterol did 
not increase the risk of stroke in the total study population, but only in subjects free 
from diabetes tnellitus and cardiovascular diseases at baseline. Since the association 
bet\veen high serum cholesterol level and coronary heart disease is already known 
for altnost four decades,38 patients suffering from coronary heart disease arc likely to 
change their diet or use lipid-Io\vedng drugs, and consequently reduce their serum 
cholesterolleve!. This probably holds for subjects suffering from diabetes or having 
a transient ischemic attack, as well. Indeed, in our study those subjects who suffered 
from cardiovascular diseases were more likely to start using lipid lowering drugs. It 
is plausible that similar differences exist regarding life style changes. Since diabetes 
mellitus and presence of cardiovascular diseases increase the risk of stroke,J9-42 this 
may result in an underestimation of the true risk associated with elevated choles-
terol, as is illustrated with our findings. 
In our analysis exclusion of subjects with cardiovascular diseases carded the addi-
tional advantage that proportionally more strokes were caused by atherothrolllbosis, 
wluch is more likely to be associated WitIl high cholesterol,43-.15 since the excluded 
subjects had a higher probability to have a cardioembolic stroke tIlan the remaining 
subjects.46 
Coronary heart disease causes another difficulty in studying the relationslup 
between cholesterol and stroke due to a strong competing risk effect.' The pattern of 
atherosclerosis follows a sequence of progression. First plaques becomes established 
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in the aorta, then in the coronary arteries, and finally in the cerebral arteries:17.48 
Subjects with high cholesterollevcls may die of myocardial infarction before occur-
rence of stroke, which results in an underestimation of the strength of association 
between cholesterol and stroke. 
In summary, our study supports the vic\v that high serum cholesterol is a risk 
factor for ischemic stroke. 
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Family history of 
cardiovascular diseases 
and risk of stroke 
The Rotterdam Study 
Background and Purpose ~ FaJl/i!y his/Of] 0/ stroke increases the n'sk oj stroke, bllt if 
relllaills IIlIclear whelher Ihis I;sk depellds ollihe age 0/ the proballd, the killd or IIII1)Jber 0/ jallli/y 
lIIelllber(s) qUieted, or the ag' al stroke ill the relali/le. Fillthen)Jole, it is IlIIdear Iphelher Ihe I;sk 
0/ sllVk~ is also illcreased flrpmolls with a positil!e jall/ily history 0/ mrdio!!asCIIlar disease. lIi'e 
stlldied these fjmstiolls ill tI prospecti!le poplllatioll based coholi. 
Methods - This stll(ly II'tIS colldllcted withill the Rntterdfll)J Stllri;, a pl~sperti!!e peplilatioll-based 
(ohort Silidy 0/ sllbjects aged 55 jean- or oller that staded ill 1990. This allalysis collce"'s 7259 
slIo/eets JJlho 1J!ere free from stroke at base/tilf) fllld }p/;ose jf/lJJi!)' bislo!), 0/ (tlrtiiollflsmlar disease 
co1i1d be assessed. 
Results - The )JIMII follow-lip lillie was 4.4 )'etll" alld 310 fin-I-e!!er sllVkes oCCllrled dfll;lIg Ihe 
follow-lip. Histol]' 0/ slroke ill allY fin-t deg"e lelalil!e sigllifimllily illmased Ihe I;sk 0/ stroke 
(ldatil" I;sk 1.3; 95% cOIl/idellce illterwtll.O, 1.6). The dsk IIYlS 8IleII higherforpmolls Ipho had 
/l/ol'e thtiH Olle re/a/i/le }}Jilh hislol)' oj strok.e or (/ fint degree re/atin 11'/;0 sl(flered jiWII a stroke 
bejim Ihe age 0/65. RIII/il)' histol]' 0/ earl)' lII),omrdial illfontioll also illmased the dsk 0/ stlVke, 
albeit 1I0t statistical/)' sigllificallt!y. 
Conelusions - Ofll-jilldillgS sllggest Ihat gelletic S/lsceplibili!y does pI(/)' a IVle ill the etiology 0/ 
stlVke, allhollgh OIIeml/ jall/ilial aggregatioll seellls 10 be 1II0desl. I-Iow8l!81; gelletic jaclon- appear 10 
be ill/pOitallt ill Mrly ollset fimllS 0/ Ihe disease. 
A lthough initial case-control or cross-sectional studies showed conflicting results,1-7 in recent years several reports from methodologically nlore robust prospective cohort studies have appeared that almost all point to an 
increased risk of stroke for persons with a positive family history of stroke.S-14 Nev-
ercile1ess, several questions have remained. It is unclear whether the risk of stroke 
varies with the kind of relative (father, mother, sibling, offspring),14 and whether 
the risk depends on the age at stroke of the relative or on the number of relatives 
affected. Furthermore, data on the relationship between family history of nlyocar-
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dial infarction and risk of stroke is scarce. 12,13,15 OUf objective was to collect further 
evidence on the relationship between family history of cardiovascular diseases and 
the occurrence of stroke. 
SUBJECTS AND METHODS 
Study population 
Tlus study was conducted in the framework of the Rotterdam Study, an ongoing 
prospective population-based cohort study for wluch all inhabitants aged 55 years or 
over, living in a suburb of Rotterdam, The Netherlands, were invited. The rationale 
and design of the Rotterdam Study have been described e1sewhere. 16 
Baseline data collection was performed between 1990 and 1993. Ylhitten informed 
consent and permission to retrieve information from medical records \verc obtained 
from every participant. The study has been approved by the Medical Etiucs Com-
nuttee of ti,e University Hospital of Rotterdam. In total 7983 subjects participated 
(response rate 78%). Among tilem 7603 subjects completed tile baseline interview 
and examination, and reported no previous stroke at baseline. Of them 7259 gave 
information on family history of stroke and myocardial infarction. 
Outcome 
Once subjects enter the study they are continuously monitored and followed through 
linkage with automated medical records of the general practitioners working in 
the study area. Furthermore, bimonthly updates from the municipality records are 
obtained. When an event or deati, is reported, additional information is obtained by 
interviewing the general practitioner and scrutinizing the medical files or hospital 
discharge records in case of admittance or referral. This analysis concerns events 
that occurred till December 31,1996. 
All suspected strokes were reviewed by a neurologist (PJK), who classified thetn 
as definite, probable or possible strokes or as non-stroke events, and detennined 
stroke subtypesY 
Determinant 
Patients were requested to describe tileir pedigree structure at home, guided by a 
structured questionnaire. Family history of stroke and myocardial infarction was 
assessed by direct questioning for each relative listed in the pedigree. For this analysis 
family history of stroke and myocardial infarction was defined as history of stroke 
or myocardial infarction of any parents, siblings or offspring. Events before or at the 
age of 65 were considered early events. 
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Potential confounders 
"'ith respect to smoking behavior subjects \vere categorized as current or former 
smokers, and those who never smoked. Diabetes mellitus was defined as random 
or post-load serum glucose level higher than 11.1 mmol/l or use of antidiabetic 
medication. IS Serum total cholesterol was determined by an automated enzymatic 
procedure.19 Hypertension was defined as systolic blood pressure equal to or higher 
than 160 mmHg, or diastolic blood pressure equal to or higher than 95 mmHg, or 
usc of antihypertensive medication.20 Prevalence of angina pectoris \vas assessed by 
means of a Dutch version of the cardiovascular questionnaire of Rose et aF' His-
tory of stroke or tnyocardial infarction was assessed primarily by direct question-
ing. Self-reported events were confirmed by additional information from the general 
practitioner, cardiologist or neurologist.22,23 
Statistical analysis 
All first-ever strokes were included in the analysis. Relative risks and 95% confi-
dence intervals were estimated through Cox-regression. To study the overall effect 
of family history of stroke we first adjusted only for age and gender. Next, to con-
trol for the effect of shared lifestyle factors and of possibly genetically determined 
specific cardiovascular risk factors, we further adjusted for stnoking habit, serum 
total cholesterol level, hypertension, diabetes mellitus, angina pectoris, coronary 
revascularisation procedure and myocardial infarction. Similar analyses were carried 
out with family history of myocardial infarction and in tills case additional analyses 
were done \vith adjusttnent for family history of stroke and early stroke. 
Separate analyses were carded out for family history of stroke and myocardial 
infarction in different first degree relatives (father, mother, sibling and offspring). 
Furthermore, we analysed the relationship according to the age at stroke or myocar-
dial infarction in first degree relatives. 
To study whether genetic hereditability of hypertension or diabetes mellitus 
could playa role in the association between family history of stroke or myocardial 
infarction and occurrence of stroke, we compared the prevalence of hypertension 
and diabetes mellitus at baseline in subjects \VitIl and \vithout family history of stroke 
or myocardial infarction. 
Missing data of potential confounders were handled by the indicator method." 
On confounders more than 900/0 of data was available except previous myocardial 
infarction (89%) and diabetes mellitus (80%). 
RESULTS 
Table 1 shows the baseline characteristics of the study population. The study 
cohort was followed for an average of 4.4 years. Among them 310 first-ever strokes 
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Characteristic 
Age (year) 
Serum cholesterol (mmolfl) 
Men 
Current smoker 
Former smoker 
Hypertension 
Diabetes mellitus 
Angina pectoris 
History of myocardial infarction 
Values are means (SO) or percentages. 
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Subjects without 
family history of 
stroke 
(n = 5102) 
69.9 (9.6) 
6.6 (1.2) 
40.5 
23.7 
40.7 
34.4 
12.9 
6.4 
12.6 
Subjects with 
family history of 
stroke 
(n = 2157) 
69.3 (B.7) 
6.7 (1.2) 
36.4 
20.2 
41.6 
39.B 
10.6 
7.7 
12.9 
occurred. Of these strokes 7.1% were hemorrhagic \17% confirmed by brain scan), 
74.8% ischemic (61% confirmed by brain scan), and 18.1% could not be specified. 
A statistically significant association between family history of stroke and the risk 
of first-ever stroke was observed (fable 2). Furthermore, those ,vith morc than one 
first degree relative with a previous stroke had a higher risk than those with only onc 
relative with stroke. 
\'\'hen different first degree relatives were considered separately, modestly 
increased risks were found for siblings and parents. The strongest relationship was 
found for history of stroke in offspring. 
Relative risks were higher when family history of early stroke was studied. Here, 
ti,e strongest risk increase was again Witll history of stroke in offspring. The risk for 
maternal history was somewhat higher then for paternal history of stroke (Table 3), 
but the difference was not statistically significant. 
\\fc found no evidence for a relationship between family history of any myocar-
dial infarction and the occurrence of sttoke. However, family history of early myo-
cardial infarction slightly increased ti,e risk of stroke, although tlus did not reach 
statistical significance (relative risk 1.2; 95% confidence interval 0.9, 1.7). Family his-
tory of myocardial infarction in more than one fast degree relative increased the risk 
further (relative risk 1.6; 95% confidence interval 0.8, 3.0). Adjustment for family 
history of stroke or early stroke did not materially change these results. 
Finany, hypertension at baseline was more frequent in persons with family his-
tory of stroke or myocardial infarction or both tllan in persons without family lus-
tory of stroke and myocardial infarction (Table 4). Tlus was not the case for diabetes 
Relative risk 
Determinant Subjects at risk Number of strokes 
Crude* Adjusted' 
No family history of stroke 5102 209 1 .0 Ireference) 1.0 Ireference) 
History of stroke 
in any first degree relative 2157 101 1.3 11.0, 1.6) 1.311.0,1.6) 
in one first degree relative 1864 81 1.2 10.9, 1.5) 1.2 10.9, 1.6) 
in more than one first degree relative 293 20 1.5 11.0, 2.4) 1.5 10.9, 2.4) 
in mother 983 40 1.2 10.8, 1.6) 1.2 10.8, 1.6) 
in father 714 29 1.3 10.9, 1.9) 1.3 (0.9, 1.9) 
in any parent 1610 64 1.2 10.9, 1.6) 1.2 10.9, 1.6) 
in sibling 674 43 1.3 10.9, 1.8) 1.3 10.9, 1.8) 
in offspring 45 5 3.211.3,7.8) 2.9 (1.2, 7.1) 
.... Adjusted for age and gender. 
t Adjusted for age, gender, smoking habit, total cholesterol, hypertension, diabetes mellitus, coronary heart disease. 
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Relative risk 
Determinant Subjects at risk Number of strokes 
Crude*' Adjusted' 
No family history of stroke 5102 209 1.0 (reference) 1.0 (reference) 
History of early stroke 
in any first degree relative 631 36 1.6(1.1,2.3) 1.6(1.1,2.3) 
in one first degree relative 600 33 1.6(1.1,2.3) 1.6 (1.1, 2.3) 
in more than One first degree relative 31 3 2.0 (0.6, 6.1) 1.9 (0.6, 6.1) 
in mother 181 12 1.8 (1.0, 3.3) 1.8 (1.0, 3.3) 
in father 174 7 1.2 (0.6, 2.6) 1.3 (0.6, 2.8) 
in any parent 350 18 1.5 (0.9, 2.5) 1.6 (1.0, 2.6) 
in sibling 278 16 1.5 (0.9, 2.5) 1.5 (0.9, 2.5) 
in offspring 26 4 3.5 (1.3, 9.6) 3.1 (1.1,8.4) 
.. Adjusted for a9-e and gender. 
t Adjusted for age, gender, smoking habit, total cholesterol, hypertension, diabetes mellitus, coronary heart disease. 
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Family history 
No family history of stroke or MI * 
History of stroke in any 15t degree relative 
History of MI in any pt degree relative 
History of both stroke and MI in 1 st degree relative 
* MI, myocardial infarction. 
t OM, diabetes mellitus. 
Prevalence of Prevalence of 
hypertension OM t 
at baseline at baseline 
(%) (%) 
33.3 
39.2 
36.3 
40.7 
13.7 
10.4 
11.0 
12.2 
mellitus. However, adjustment for these and other major stroke risk factors did not 
change the results suggesting that tlus could not explain the relation betwecn posi-
tive family lustory of stroke and occurrence of stroke (fable 2 and Table 3). 
Exclusion of hemorrhagic strokes did not materially change any of our results. 
DISCUSSION 
\\le found a relationship bet\veen family history of cardiovascular diseases and occur-
rence of first-ever stroke. History of stroke in any first degree relative increased the 
risk of stroke by 30 percent, and the risk was lugher if the stroke occurred before 
age 65 years in the relative. Similarly, although to a lesser extent, family history of 
early myocardial infarction increased tl,e risk of stroke. To our knowledge this is the 
first study \vhich showed an increasing risk of stroke with increasing number of first 
degree relatives who had had a stroke. 
We should note that our study has some linutations. First of ail, stroke is a het-
erogeneous group of disorders. Unfortunately, \ve did not have enough information 
to usc detailed categorisation of cases according to the assumed patllOphysiology. 
Nevertheless, we could at least classify major subtypes of strokes. Since only 7 per-
cent of all cases were hemorrhagic strokes they could not be analysed separately. 
Although our primary analysis included all first-ever strokes, exclusion of hemor-
rhagic strokes did not materially change the results. 
Family history of stroke \vas assessed as part of the baseline intervie\"'\,; Since 
this information was not verified some misclassification could occur. Family history 
of myocardial infarction is more frequently under- than overreported,25.-28 and it is 
likely that the same holds for fanuly history of stroke. Consequently, our results 
somewhat underestimate the true risk of stroke associated with positive family his-
tory of cardiovascular diseases. 
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Our estimated relative risk of stroke in subjects with family history of stroke is 
somewhat lower than the result (relative risk 1.6; 95% confidence interval 1.0, 2.4) 
from the Family Heart Stud)\ which is a multicenter study involving subjects from 
foUl' different cohorts. I' This study has also reported the risk separately for subjects 
with positive family history of stroke in different first degree relatives. Contrary to 
OUl' results the Family Heart Study found no cvidence that history of stroke in sib-
lings or .in offspring increases dlC risk of strokc.14 However, the risk estimates in the 
Family Heart Study have wide confidence intervals ovcrlapping the estimatcs from 
our study. 
Regarding the higher risk in subjects with family history of early stroke, OUl' find-
ings are in line with the results of Jousilahti et aL 13 They found in a prospectivc 
follow-up study of 14371 middlc aged subjects that history of stroke in parents 
before age 60 increascd the risk of any stroke in men and women by 90 and 73 
percent, respectively, and of ischemic stroke by 53 and 71 pcr cent. In addition to 
that wc found and increased risk in subjects with a child or sibling who had had a 
stroke before age 65. Unfortunately, the Finnish study did not present data on family 
history of stroke above age 60, thus the relativc inlpact of age at stroke can not be 
directly judged from their report. 
In OUl' study tl,e estimated risk of stroke did not differ much in subjects with 
tnaternal or paternal history of stroke, but maternal history of early stroke increased 
the risk of stroke more than paternal history. Available data regarding this issue is 
controversial. Results from the Framingham Study, tl,e Family Heart Study and from 
the study of Jousilahti et aL showed 19 to 96% higher risks with paternal history 
than with maternal history,u,13,14 On the other hand, \,'elin et al. reported maternal 
but not paternal history of deatll of stroke as an independent risk factor for stroke,' 
altllOugh this finding was not confirmed by the study of Wannamethee et al. 12 
Previous results about the relationship between family history of myocardial 
infarction and risk of stroke ,vere controversial. In an Italian case-control study 
no association was found,15 in a British cohort parental death from heart trouble 
increased the risk of stroke, and this risk was virtually not modified by parental age 
at death,12 and in a Finnish cohort parental history of coronary heart disease before 
age 60 increased tl,e risk of both an)' stroke and ischemic sttokeP Our fmdings 
confirm the Finnish results. 
In our study hypertension was more frequent at baseline in subjects \vith family 
history of stroke or myocardial infarction than in subjects \vith no family history 
of these disorders. This may indicate a partly common genetical pathway of the dis-
eases. Nevertheless, our analysis showed that adjustment for major stroke risk fac-
tors, including hypertension, did not change the results. Therefore, shared life-style 
factors and inheritance of conventional vascular risk factors cannot fully explain our 
findings. Although shared environment may contribute to the familial aggregation 
of stroke, we think that our study strongly supports that genetic susceptibility plays 
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an important role in the etiology of stroke. 
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Dietary antioxidants 
prevent stroke in smokers 
The Rotterdam Study 
High iJltak.e rf frlllIS, lJ/'talllill C, /3-mrotelle, or selellilllJJ pre-pel/ted stroke iJ/ a (oh0l1 qf Dille/; 
elderly people. The protedille effect was col!filled to smoke!>: 
O xidative stress reportedly plays a role in the etiology of stroke. Therefore dietary intake of antioxidants might lower the risk of stroke. High intake of fruits has been reported to protect against stroke. l The joint investiga-
tion of the Nurses' Health Study and of the Health Professionals' Follow-up Study 
also found a protective effect of fruits and vegetables and the effect was slightly 
stronger in smokers than in non-smokers.2 It has been suggested that dietary anti-
oxidants may account for the beneficial effects of fruits and vegetables.3 OUf aim 
was to investigate the relationship between specific dietary antioxidants, including 
flavonoids, antioxidant vitamins, and selenium and the risk of stroke, and to assess 
whether the putative protective effect of these antioxidants differs bChveen slnokcrs 
and non-smokers. 
This study was conducted within the Rotterdam Study, an ongoing prospective 
population-based cohort study for which all inhabitants aged 55 years or over, living 
in a suburb of Rotterdam, The Netllerlands, were invited.' Baseline data collection 
was performed between 1990 and 1993, and the total cohort consists of 7983 sub-
jects (response rate 78%). 
At baseline, a modified 170-item semiquantitative food frequency questionnaire 
was applied in two steps for dietary assessment. During a home interview subjects 
filled in a simple questionnaire, and then during a subsequent visit to the research 
center a trained dietician interviewed them.' 7006 subjects completed the baseline 
interview and examination. The food frequency questionnaire was not administered 
to subjects participating in the pilot study (n=277), living in nursing homes (n=479), 
subjects with known reduced cognitive function (n=122) and an additional 482 
subjects due to logistic reasons (no dietician available). F!'Om the 5646 with food 
frequency data 5234 subjects reported no previous st!'Oke at baseline and had a com-
plete follo,v-up, and these wcre included in this analysis. 
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History of stroke was assessed primarily by direct questioning. Self-reported events 
were confirmed by additional information fr01n the general practitioner or neurolo-
gist. During follow-up subjects are continuously monitored through linkage with 
automated medical records of the general practitioners working in the srudy area. 
Furthermore, bimonthly updates from the municipality records are obtained. When 
an event or death is reported, additional information is obtained by interviewing the 
general practitioner and scrutinising the medical files or hospital discharge records 
in case of admittance or referral. All suspected stroke cases that were reported 
were reviewed by a neurologist (PJK), who classified the stroke as definite, probable 
or possible and defined subtypes. This analysis concerns strokes that occurred till 
December 31, 1996. 
Relative risks (and 95% confidence intervals) of stroke for specific antioxidant 
intakes were estimated through Cox-regression, adjusted for age and gender. Dietary 
intake items - vitamin C, vitamin E, p-carotene, flavonoids, selenium, total food 
energy - were categorised in terriles (low medium and high intake). Those who were 
taking vitamin supplements were included in the highest terrile for the concerning 
analysis. All analyses were adjusted for total energy intake. For the analysis of vita-
min E intake we additionally adjusted for polyunsarurated fatty acid intake. Since 
diet is likely associated with health behaviour and the health status of an individual 
we also adjusted for smoking, hypertension, diabetes mellitus, history of coronary 
heart disease and transient neurological attacks. To assess possible effect modifica-
tion by smoking status, we performed analyses separately for current-smokers and 
non-smokers (including former smokers). Furthermore, to assess the independent 
effect of the different dietary components, we fitted models with inclusion of all 
antioxidants under study. 
The study cohort was followed for an average of 4.7 years. Among them 173 first-
ever strokes occurred. Of these strokes 8.7% were hemorrhagic, 79.20/0 ischemic, 
and 12.1% could not be specified. 
Higher intake of vitamin C, p-carotene, and selenium was associated with a lower 
risk of stroke in the total srudy population (Table 1). Stratification for smoking 
behaviour showed that this protective effect was confined to smokers. This nlay be 
because smokers have higher free radical activity, as reflected by the higher level of 
free radical activity mediated lipid peroxidation products in their blood. Consump-
tion of fruits and flavonoids also considerably decreased the risk of stroke in smok-
ers, although the latter did not reach statistical significance (Table 1). Inclusion of all 
antioxidants under srudy in the statistical model did not materially change the results 
for the individual risk factors. Intake of vegetables and vitamin E was not associated 
with the risk of stroke. 
Our results show that high intake of vitamin C and p-carotene may pt'otect 
against stroke in smokers. High intake of selenium, which plays a very important 
role in oxidant defence, seems also beneficial in preventing stroke. 
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Relative risk* 
Determinant ---------------
Total population Non-smokers Smokers 
-----,-----------
Fruits 
2nd tertile 1.2 (0.8, 1.7) 1.5 (0.9, 2.5) 0.7 (0.4, 1.5) 
3 rd tertile 1.0 (0.7, 1.5) 1.4 (0.8, 2.2) 0.3 (0.1, 0.8) 
Vegetables 
2nd tertile 0.9 (0.6, 1.4) 1.0 (0.7,1.6) 0.7 (0.3, 1.6) 
31d tertile 1.0 (0.7, 1.5) 0.9 (0.6, 1.5) 1.2 (0.6, 2.5) 
Vitamin C 
2nd tertile 0.7 (0.5, 1.0) 0.9 (0.6, 1.4) 0.3 (0.2, 0.8) 
3 rd tertile 0.7 (0.5, 1.0) 1.0 (0.6, 1.5) 0.2 (0.1, 0.5) 
Vitamin E 
2nd tertile 1.3 (0.8, 2.0) 1.3 (0.8, 2.1) 1.3 (0.5, 2.9) 
31d tertile 1.2 (0.7, 2.3) 1.3 (0.6, 2.7) 0.9 (0.3, 3.2) 
~-carotene 
200 tertile 0.7 (0.5, 1.0) 0.8 (0.5,1.3) 0.4 (0.2, 0.9) 
3 rd tertile 0.7 (0.5, 1.1) 0.8 (0.5, 1.3) 0.5 (0.2, 1.1) 
Flavonoids 
2nd tertile 1.1 (0.8, 1.6) 1.2 (0.8, 1.9) 1.0 (0.5, 1.9) 
3 rd terti Ie 0.8 (0.5, 1.2) 0.9 (0.6, 1.5) 0.4 (0.2, 1.2) 
Selenium 
2nd tertile 0.6 (0.4, 0.9) 0.8 (0.5, 1.2) 0.3 (0.1, 0.7) 
3rd tertile 0.6 (0.4, 1.0) 0.9 (0.5, 1.5) 0.2 (0.1, 0.6) 
* First (lowest) tertile is the reference. 
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Aspirin use and risk of stroke 
in the elderly 
The Rotterdam Study 
The objetlille of Ihe Sllld)' II'f1S 10 assess the assorialioll belweell aspilill lise tlIid the Jisk of stroke 
ill a poplllatioll-based stlld)' ill the elderly, 'Ille Stlldy was ranied Ollt witbill the }imlleJPork of the 
Rotterdalll Stlld)j a prospectille poplllatioll-based rohOit Stlld)'. III the total Stlld)' pOPlllatiOIl thm 
JPaJ a JjJeak) lIoJ/-significant assoriatioll behl'ecll aspifill lise aJ/d the risk of stroke (ar!;ilslfd relalilJ8 
Jisk 1.29, 95% CI 0.91-1.83). Stmtifiratioll by histOl]' of IlasCltlar diseases '"/lealed thai aspilill 
(ollsidembly illmased the lisk of fi,,·t eller stmke ill sllb)ects}i.e FOIJJ IJasmlar disease, (adjllsted 
relatille lisk 1.80; 95% CI 1.03-3.13). III pmolls with I'fISCltlar disftlse 110 assoriatioll was 
obseJ'1Jed belweell aspilillllse alld lisk of stmke, (adjllsled relatille lisk 0.99, 95% CI 0.56-1.73). 
Ollrfilldillg slIggesllha/ aspilill lise lilt!)' illcrease the Jisk of stroke ill eldedy sllb)erts }i.e FOIII 
[klSClt/tlJ' disease. 
lttldOmiSed clinical trials have shown that aspirin can prevent stroke in patients after a transient ischemic attack or mInor stroke.1 On the other land, the role of aspirin in primary stroke prevention is not clear. Two large 
clinical trials and a meta-analysis have even suggested that aspirin may increase the 
risk of stroke, in particular hemonhagic stroke, in low risk subjects, but this finding 
,vas not statistically significant. 1-3 Recently, it was reported from the Cardiovascular 
Health Study that aspirin usc increased the risk of stroke in aspirin using elderly 
women free from cardiovascular diseases.4 
W/e further investigated tile association behveen aspirin use and occurrence of 
stroke in a popularion-based cohort snIdy in Dutch elderly. 
METHODS 
Study population 
This study was conducted within the framework of the Rotterdam Study, an ongo~ 
ing prospective population-based cohort study for which all inhabitants aged 55 
years or over, of a suburb of Rotterdam, The Netherlands, were invited. Institution~ 
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alised persons are included. The rationale and design of the Rotterdam Study have 
been described elsewhere,s In sU1111nary, the objective of the study is to investigate 
determinants of neurogerlatrlc, cardiovascular, locomotor and ophtaltnologic elis-
eases in the elderly. 
In total 7983 subjects participated in the baseline examination (response rate 
78%). Because our aim was to study the effect of aspirin use in primary prevention 
of stroke we excluded participants who had a history of stroke at baseline, leaving 
7725 subjects. Among them there were 7431 subjects whose drug use was ascer-
tained. The 294 excluded subjects were older than the rest of the cohort, their mean 
(SD) age was 74.7 (12.0) years; 99 (34%) of them were men. After exclusion of 
subjects who used oral anticoagulation or antiplatelet therapy other than aspirin, 
the cohort comprised 7153 subjects. The incidence rate of stroke among these 
excluded subjects was higher than in the rest of the cohort: 14.9 versus 10.6/1000 
person-years. Baseline data collection was performed between 1990 and 1993, when 
all study subjects ,""erc interviewed at their homes and subsequently examined at 
a research center. Informed consent and permission to retrieve information fro111 
tnedical records were obtained from every participant. 
Assesstnent of strokes 
At baseline, information on health status and medical history was obtained using 
a computerised questionnaire. Previous stroke was assessed by direct questioning: 
"Did you ever suffer from a stroke diagnosed by a physician?". If the answer was 
'yes', medical records were checked for additional information. A previous stroke 
,vas coded if it was confirmed by medical records.6 
Once subjects enter the Rotterdam Study they arc continuously monitored for 
major events rllfough automated linkage with the files from the GPs. General prac-
titioners who send information on all possible events and deaths on a regular basis 
cover together 85% of the cohort. The general practitioners of the remainder of 
the cohort are contacted once a year to obtain foHow-up information. WTith respect 
to the vital status, information is obtained at regular intervals from the municipal 
authorities in Rotterdam. WThen an event or death has been reported, additional 
information is obtained by interviewing the GP and scrutinising information from 
hospital discharge records in case of achnittance or referral. Information on all pos-
sible strokes was reviewed by a neurologist (PJK) who classified the stroke as defi-
nite, probable or possible. The stroke was considered definite if the diagnosis was 
based on both clinical symptoms and neuro-imaging. A probable stroke was consid-
ered if no CT or MRI was made but if symptoms were highly suggestive for stroke 
according to the GP or treating neurologist. In case of fatal stroke a cardiac cause 
of death should have been excluded to reach a diagnosis of probable stroke. The 
stroke ,vas considered possible if a neurologist diagnosed a 'possible stroke' wicil0Ut 
neuro-imaging, or if a GP recorded a fatal stroke and could not exclude a cardiac 
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cause of death. 
If CT or MRI was performed which showed a haemorrhage or infarct the type of 
stroke was coded accordingly. In case of no abnormality on CT or MRl the stroke 
was classified as ischemic. When no CT or ]\000 was performed, a stroke could 
be coded possible hemorrhagic or ischemic in case of typical complaints or case 
history. A case history of sudden hemiplegia or other focal signs with permanent 
unconsciousness or death ,vithin hours without neuro-imaging was coded as possi-
ble hemorrhagic stroke. If there was limited impairment, i.e. isolated afasia, isolated 
weakness of one limb, isolated facial weakness or isolated hemianopia the stroke 
was considered possible ischemic. Furthermore, in case of complete improvement 
within 72 hours or documented atrial fibrillation at time of the diagnosis dle stroke 
also was considered possible ischemic. 
This analysis concerns events that occurred until March 1, 1996. Complete fol-
low-up was available for 6385 subjects (86%). 
Determinant 
Drug use was ascertained as part of the baseline interview ,vhen participants were 
asked to show all drugs they were using regularly at that time. 1-Icclication was classi-
fied by ATC codes.' Aspirin users were defined as persons who were regularly taking 
acetylsalicylic acid or its calcium salt (calcium carbasalate) at the time of the baseline 
intervie,,'; 
Potential confounders 
Cerebrovascular risk indicators and history of stroke were assessed at baseline exam-
ination. \X/ith respect to smoking behaviour subjects were categorised as current or 
former smokers, and those who never smoked. Diabetes mellitus was defined as 
random or post-load setum glucose level higher than 11.1 mmol/l or use of antidi-
abetic medication.8 Sitting blood pressure was measured at the right upper arm with 
a random-zero sphygmomanometer.9 The average of two measurements obtained 
on one occasion, separated by a count of the pulse rate, was used in this analysis. 
Prevalence of angina pectoris and claudication was assessed by means of a Dutch 
version of the cardiovascular questionnaire of Rose et al.lO Chest pain and paln in 
the legs but not fulfilling Rose criteria were assessed by the questions "I-lave you 
ever had any pain or discomfort in your chest?" and "Do you get pain or a feeling 
of severe tiredness in either leg on walking?", respectively. These symptoms were 
considered potential confounders because they might have served as an indication 
for aspirin use and were associated with stroke in our data, thus controHing for 
them reduces the potential bias of confounding by indication. A history of transient 
ischemic attack (rIA) was assessed on the basis of answers to the question ((Did 
you experience a short period with disturbances of sensibility jn your face, arms, or 
legs, which had lasted less than 24 hours over the last 3 years?". S.itnilar questions 
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were asked for disturbances in strength, speech, and vision. If a positive answer 
was given, more detailed information was obtained, and dlC event was categorised 
as typical transient ischemic attack (rIA), atypical TIA or no TlA, by a neurologist 
(PJK).II History of myocardial infarction (MI) was assessed primarily by direct 
questioning. Myocardial infarction was considered to have happened if it was self-
reported and ECG characteristics matched, e.g. padl0logical Q-waves or significant 
loss of R-wave potential in the precordial leads of a single ECG was seen, or it was 
confirmed by additional information from the general practitioner or cardiologist 
based on elevated cardiac enzymes or prior ECG abnormalities. In addition J'vfI was 
also considered if ECG findings was typical for "'II, regardless of d,e absence of 
symptoms.12 
Statistical analysis 
\"X'e compared the risk of first-ever stroke in aspirin users vs. non-users by estimat-
ing relative risk (RR) and 95 % confidence intervals (CI) dllough Cox's proportional 
hazards regression. All first-ever strokes were included in the analysis. Additional 
analyses were carried out on ischemic strokes and with the exclusion of possible 
strokes. 
Analyses were adjusted for age and gender. In order to control for confounding 
by indication as tnuch as possible, additional adjustment was done for the fol-
lmving cerebrovascular risk indicators: smoking habit, diabetes mellitus, systolic 
blood pressure, antihypertensive medication, presence of atrial fibrillation on EeG, 
angina pectoris, intermittent claudication, chest pain, pain in the leg, history of 
coronary revascularisation procedure (including percutaneous trans arterial coronary 
angioplasty, and coronary bypass surgery), myocardial infarction, typical and atypical 
TIA. 
To study whether the effect of aspirin was different for subjects at high or low 
risk of stroke stratified analyses were performed for subjects with or \vithout vas-
cular disease. Vascular disease was defined as history of typical or atypical TIA, 
intermittent claudication, angina pectoris, coronary revascularisation procedure or 
myocardial infarction, or presence of atrial fibrillation on EeG at entry. There were 
5508 subjects whose history of vascular disease could be ascertained. Subjects with 
vascular disease \vas older than subjects \vithout vascular disease, mean agc(SD) 72.5 
(8.9) versus 67.9 (8.5) years, and d,ere were relatively more men among d,em, 47.3 
versus 37.00/0. 
Missing data on potential confounders were handled b)' the indicator method.13 
Use of 1nlputation or total dataset methods produced essentially the same results. 
For all variables less than 10 percent of data was missing. 
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Characteristic 
Age (year) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Serum cholesterol (mmol/i) 
Men 
Current smoker 
Former smoker 
Diabetes mellitus 
Atrial fibrillation 
Intermittent claudication 
Angina pectoris 
Coronary revascularisation 
History of myocardial infarction 
History of typical TIA 
History of atypical TIA 
Values are means (SO) or percentages. 
RESULTS 
Aspirin users 
(n=662) 
73.0 (9.5) 
140.8 (23.0) 
72.7 (11.6) 
6.5 (1.2) 
48.9 
20.9 
46.5 
15.2 
4.8 
2.6 
15.0 
13.6 
29.8 
9.1 
6.7 
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Aspirin non-users 
(n=5723) 
69.6 (9.2) 
139.7 (22.3) 
74.0 (11.8) 
6.6 (1.2) 
36.9 
22.5 
40.0 
10.7 
2.0 
1.3 
5.6 
1.3 
9.9 
0.5 
1.2 
Table 1 shows the baseline characteristics of the study population. Ten percent of 
subjects used acetylsalicylic acid or its calcium salt in tlus cohort. Of these subjects 
47% used acetylsalicylic acid, 52% calcium carbasalate and 1% both. 66% of drug 
users ,vere taking their drug daily, and 950/0 of the users took a tablet at least once 
every three days, and the remaining 5% of subjects v,rere taking acetylsalicylic acid 
weekly. Of the 44 subjects who suffered a stroke and were taking medication 17 
used aspirin and 27 used calcium carbasalate. The mean defined daily dose of the 
drug was 249mg, 90% of the users took no more than 500mg per day. There was no 
difference in dosage between subjects with or without history of vascular diseases. 
Those who suffered a stroke during the follmv-up took neither lllore nor less drug 
than those who had no stroke. 
The shldy cohort was followed for an average of 3.9 years. In total, 265 strokes 
occurred until the end of follow-up, 220 of wluch were definite or probable. Of all 
strokes) 8.30/0 ,,,ere hemorrhagic, 73.6% ischemic) and 18.1 % non-specified. From 
the 44 stroke cases that occurred among aspirin users 29 ,vere ischemic) three ,vere 
hemorrhagic, one was subarachnoid haemorrhage and eleven were unspecified. 
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Total study 
population 
non-users 5723 221 9.8 1.0 (reference) 1.0 (reference) 
users 662 44 18.3 1.42 (1.03-1.98) 1.2910.91-1.83) 
Without 
vascular disease 
non-users 3946 106 6.9 1 .0 (reference) 1.0 (reference) 
users 227 15 18.1 1.76 (1.02-3.05) 1.80 (1 .03-3.13) 
With vascular 
disease 
non-users 984 65 17.1 1 .0 (reference) 1.0 (reference) 
users 351 19 15.1 0.90 10.54-1.50) 0.99 (0.56-1.73) 
CI: confidence interval. 
* Adjusted additionally for smoking habit, diabetes mellitus, systolic blood pressure, 
antihypertensive drug use, atrial fibrillation. intermittent claudication, angina pectoris, chest 
pain. pain in the legs, coronary revascularisation procedure. history of myocardial infarction. 
history of typical and atypical TIA. 
In the total cohort, there was a weak, non-significant association behveen aspi-
rin use and the risk of any stroke (fable 2). In the stratum of subjects without 
vascular diseases aspirin use almost doubled the risk of stroke, (RR 1.80; 95% CI 
1.03~3.13). Separate analyses for men and women produced essentially the same 
results widl \vider confidence intervals. lunong subjects with vascular disease there 
\vas no association between aspirin usc and the risk of stroke, (RR 0.99; 950/0 CI: 
0.56-1.73). Exclusion of possible cases only marginally changed these results RR 
1.91 (1.05-3.48) and RR 0.94 (0.52-1.70) for subjects without and with vascular dis-
eases, respectively. 
Our analysis included all types of stroke. Of the 15 cases that occurred in sub-
jects free from vascular disease and using aspirin one stroke was subarachnoid haem-
orrhage, and t:\vo were intracerebral haemorrhage. \\!hen only ischemic stroke was 
considered the estimated relative risk was 1.09 (0.71~1.67) in the total study popula-
tion, RR 1.46 (0.73~2.96) and RR 0.87 (0.45-1.69) in the strata of subjects without 
and with vascular disease, respectively. 
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DISCUSSION 
In this population-based study wc found that aspirin use is associated with an 
increased risk of any stroke, but only in subjects without vascular disease. The risk 
of ischemic stroke increased as well, albeit less than the risk of all strokes, and not 
statistically significantly. 
The result is consistent v.rith previous studies. Aspirin was shown to be effective 
in prevention of myocardial infarction, stroke, and vascular death in subjects with 
prior myocardial infarction, stroke, transient ischemic attacks, unstable angina, revas-
cularlsation surgery, angioplasty, atrial fibrillation, valvular disease, and peripheral 
vascular disease. I However, the role of aspirin in primary prevention is not yet 
established. Results from trials of primary prevention among men showed a non-
significant increased risk of stroke among aspirin users,l-3 and an increased risk of 
ischemic stroke has been reported recently, as well from the Cardiovascular Health 
Study among elderly ,vomen free from vascular diseases ,vho used aspirin.4,14 
\\lhat might explain the increased risk of stroke associated with aspirin use in low 
risk subjects? The possibility of an increase in the incidence of hemorrhagic stroke 
in aspirin users is not unexpected. But in addition, aspirin may have a paradoxical 
tllrombogenic effect,. probably by inhibition of PGI2 production in endotllelial 
cells. IS Recent reports have shown that aspirin antagonizes tissue plasminogen acti-
vator mecliated thrombolysis, probably by inhibiting the expression of the induc-
ible nitric oxide synthase. I6-19 These mechanisms tnay explain the potential adverse 
effect of aspirin on tl,e incidcnce of ischemic stroke. If aspirin has a paradoxical 
thrombotic side effect, it is expected to be detected in subjects who have very little 
to gain from its beneficial effect, i.e. in subjects without vascular disease. 
A potential weakness of our study originates from the difficulties in exposure 
status assessment. It was suggested that aspirin taken occasionally as an antiinflam-
matory meclication or pain killer during the follow-up could bias the result of the 
studies on aspirin use in which aspirin use is assessed at entry.20 Indeed, it is possible 
tl1at stroke is associated with tIus type of drug use as well. Ho\vever, since it is very 
likely that occasional use of aspirin as antiinflammatory drug is at least as frequent 
among subjects who are not using aspirin regularly as among regular aspirin users, 
this can not explain our result. Furthermore, it is entirely possible that some subjects 
started using aspirin regularly after baseline examination. Nevertheless, this would 
result in an underestimation of the effect of aspirin) therefore our estimate can be 
considered as a conservative one. 
One might argue tl,at tl,e association found between aspirin use and risk of 
stroke is not causal but due to confouncling by indication. We reduced this possibility 
by including all known major risk factors for vascular disease in the analysis and \ve 
carried out separate analyses in subjects witl1 and without vascular disease, as well. 
Since we can not think of an indication for aspirin other than those considered in 
this study, which itself increased the risk of stroke, it is very unlikely tl,at confound-
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log by indication explains Qur result. 
Another alternative explanation to causal relation between aspirin use and risk 
of stroke could be that the group of aspirin users include subjects who stopped 
aspirin usc before the occurrence of stroke,20 and the rebound effect was responsi-
ble for stroke,21,22 However, if aspirin were beneficial in prevention of stroke in low 
risk subjects then it would have to be entirely overwhelmed by the adverse rebound 
effect in our study, which could occur if many subjects stopped taking the drug, or 
if stopping the treatment enormously increased the risk of stroke, even in subjects 
with an otherwise very lov,r risk. In our vic\v a more plausible explanation is that 
aspirin can not prevent stroke in low risk subjects, and that aspirin has an adverse 
effect, maybe partly due to stopping medication. 
In conclusion, our results indicate that aspirin use may be associated with an 
increased risk of stroke in elderly people \vithout a history of vascular diseases and 
atrial fibrillation. This finding needs fur ti,er study, which should address the effects 
of aspirin on all major vascular events - stroke, myocardial infarction, and death - to 
study the net effect of aspirin use in primary prevention in elderly people. Even if 
the net effect is beneficial considering all benefits and harms of aspirin use, it may 
be possible to identify subgroups of subjects who gain and who lose with the use 
of aspirin in prevention of cardiovascular diseases. Evidence on safety of a drug 
used for primary prevention should be stringent, since its beneficial effect is usu-
ally minimal in individuals, who are at lo,v risk anyway, and can be offset by side 
effects.v 
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Prevention of stroke 
by carotid endarterectomy. 
A Bayesian random effect 
meta-analysis 
The Stlldy assessed the effect 0[ carotid elldmtmctomy 011 ali-wise IJ/011ality alld strokefree Sill' 
Ilillal based 011 the combilled data ji"om mlldomized Ilials. We semrhed for all Pllblished mlldomized 
clinical tlials in l}Jhich carotid endtllterectolJD' J}/as cOlJlpared to lJIedical treatll1mt. f-,.,Tine tn'als that 
lI1et pre-specified cliteda )Jfere located. For each lIial identiral lJleaSllres 0/ diseflse jreqllcJl(Y )}Jere 
calClilaled ji'OJ/I Pllblished dala, alld were allfllyzed IIJ regressioll allalysis follO/llillg a Bayesiall 
approach. Cm'Olid elldmtemtoJ/I)' does 1101 illcrease lifo expectallCY IlIIt prolollgs strokeji.e sllmiva/. 
This belleficial effect after thm j'ean 0[ opemtioll is preselll Ollly whell the estimated illridellce mte 
0[ stroke 01' death ill patimt receMllg ollb' lIIedical Inatmelll is abolle abollt 8.3 per 100 patiellt-
)'ffll'·. With illcreasillg lisk 0[ strok£ or dealh SIll'fPJ' becomes III0re €ffeclive. Cm'Olid CIIdm1mc-
10111)' prolollgs strohji.e slll'llival bllt its applimtioll shollld be limited to paliellts al high fisk 0[ 
stroke. 
I n developed countries stroke is the third leading cause of death. Its annual inci-dence is about 0.15 percent.' The first year survival probability is less than 75 percent and one year after the event more than 25 percent of the survivors are 
unable to function independently.' 
It is estimated that 20-30 percent of stroke cases is related to carotid artery ste-
nosis. The underlying mechanism is usually thromboembolism) originating frotn an 
atherosclerotic plaque of the internal carotid artery,3 Carotid endarterectomy aims 
to remove the plaque and restore the lumen of the vessel. This is a frequently per-
formed vascular surgical procedure:" Although the first published operation was 
carried out decades ago,' and more tl,an I million people have been operated since 
1980 in the United States only,' there are still unanswered questions regarding the 
efficacy of carotid endarterectotny in the prevention of cerebral infarction and 
death.7-17 Many observational studies and several clinical trials comparing carotid 
endarterectomy plus best tnedical care with tnedical treatment alone have been done 
or are under way. 
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This paper is a quantitative analysis of the randomized clinical trials addressing this 
question published thus far. Our aim ,vas to assess the safety of carotid endarterec-
tomy by compating the one-month incidence of death, and the combined event of 
stroke or death between the surgical and the medical arms of the trials reported. 
Furthermore, we wanted to assess whether carotid endarterectomy improves long-
tenn survival and stroke-free survival. Other parameters of interest were therefore 
the incidence rate ratios of death, and of the combined event stroke or deadl (inci-
dence rates expressed as number of events per person-years of follow-up 'at risk') 
from the first nlonth onwards. In the statistical analysis a regression method was 
applied using a Bayesian approach with non-informative priors. IS•19 Our medlOd can 
be considered as a generalization of the medlOd described by Thompson et al.,'" 
taking into consideration the comments of van Houwelingen and Scnn.21 
MATERIALS AND METHODS 
Selection of trials 
\'?e searched the Medline database for all published randomized clinical ttials in 
which one of the treatment arms was carotid endarterectomy. \,/e completed the 
search by checking the references of the articles found. Eleyen trials that met this 
criterion were located,22-3.3 Those trials were included in the analysis that fulfilled the 
following pre-defined criteria: 
1. The indication of carotid endarterectomy was stroke prevention rather than 
treatment of acute stroke. 
2. The methodology of the trial as described was judged appropriate (no excessive 
loss to follow-up, synunetrlcal outcome assessment, analyzed by treatment assign-
Inent from the moment of randomization on\vards). 
3. The parameters of interest in this analysis could be calculated from published 
data, or from additional data obtained by writing to the author of d,e original 
report. 
Prom the Joint study of extmcmnial arterial occlusion only a separately published 
subgroup fulfilled d,e above criteria.22 The subgroups based on the degree of carotid 
artery stenosis of the European Carotid Surgery Trial and of the North American 
Symptomatic Carotid Endarterectomy Trial \vere analyzed separately in tills over-
view.25,32,33 
The following trials were excluded. About one trial in 230 patients only a short 
summary was published and it 'vas not possible to obtain the information rccluircd,JO 
The trial carried out at d,e Mayo Clinics (71 patients) was excluded because d,e 
parameters of interest could not be calculated from the available data.28 Fr0111 one 
trial report only stroke-free suryival could be estimated.26 In one trial report data on 
any strokes \vere not available and our analysis concerns tnajor strokes - producing 
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symptoms for more than seven days.32 
Table 1 shows some characteristics of the trials included in the analysis. It is 
noted that in the trials involving subjects with high grade stenosis the comparison 
was bet\vecn immediate surgery combined with medical therapy and medical therapy 
alone. In several trials involving subjects with moderate, slight or aSYlnptomatic ste-
nosis the effect of hnmcdiate surgery and waiting policy, i.e. avoiding the operation 
as long as possible was compared. 
In total, our analysis concerns 8991 patients, 4780 allocated to surgery and 4211 
to medical treatment. 
Data extraction from individual trials 
The follow-up period was split up into two parts: the fIrst n10nth post-operative 
period and d,e period after d,e first month until three years. To caleulate the first 
month cumulative incidence of stroke or death in the surgical group the number 
of events were divided by the number of patients 'at risk') which was taken as the 
number of subjects enrolled in a group, and it was assumed that no patient was lost 
to follow-up in the first month. 
\\!hen stroke-free survival curves were given,25,29,31 the combined incidence rates 
of stroke and death from the first month onwards for d,e surgical and from d,e ran-
domization onwards for the medically treated cohorts respectively \vere estitnated as 
follows. For the n1edical cohorts the stroke-free survival probability closest to three 
years was read off fr01n the curve and converted to an incidence rate with the use of 
the following equations, assuming exponential stroke-free survival with a constant 
incidence rate from the moment of randomization onwards: 
CI,\j (/) = 1- e -!R"" 
From this we have 
In(l- CI,u (I» 
-/ 
equation 1 
equation 2 
where C~\f(tJ and IR,u denote the t -year cumulative incidence and incidence rate, 
respectively, in the medical group. 
For the surgical cohorts the stroke-free survival probability at the same time 
point was determined as the product of the one-month stroke-free survival prob-
ability and the stroke-free survival probability from the first month onwards. Hence, 
the stroke-free survival probability at three years was divided by the one-month 
stroke-free survival probability (as estimated the way stated previously) to obtain 
the stroke-free survival probability from d,e first mondl onwards. The latter was 
again converted to an incidence rate, assuming exponential stroke-free surv1\ral \vith 
a constant incidence rate from the first month onwards. Thus the following equa-
Study 
Joint study'O 
Shaw et al." 
Veteran 30924 
ECST'O 
NASCET23, " 
Symptoms before entry 
TIA' 
no neurological deficit 
symptoms of carotid artery 
d:isease 
TIA, TMB' or small completed 
stroke within 120 days 
TIA, TMB or nondisabling stroke 
within 6 months 
TIA, TMB or nondisabling stroke 
within 120 days 
Angiologic requirements of eligibility 
ICA t stenosis> 30% on angiogram 
occlusions excluded 
operable ICA lesion on angiogram 
ICA stenosis ~ 50% on angiogram 
occlusions excluded 
no more severe intracranial lesion 
leA lesion on angiogram 
no clear treatment preference of the 
treating physician 
no more severe intracranial lesion 
ICA stenosis ~ 30% on angiogram 
occlusions excluded 
no more severe intracranial lesion 
Clagett et al." no history of TIA, TMB, or stroke abnormal OPPG1 
absence of nonfocal cerebro-
CASANOVA" 
vascular symptoms 
no neurological symptoms 
no subclavian steal 
ICA stenosis 51-89% on angiogram 
no intracranial, CCA#$ or bilateral 
vertebral artery stenosis> 50% 
Treatment comparison 
CEA' + medical treatment vs, 
medical treatment (unspecified) 
CEA VS. medical treatment (unspecified) 
CEA + best medical care vs. best medical 
care (incl. 325 mg aspirin/day) 
CEA + best medical care vs. best medical 
care (usually included aspirin) 
12 % operated in the medical group 
CEA + best medical care VS. best medical 
care (incl. 1300 mg aspirin/day) 
18% with stenosis less than 70% and 6% 
with stenosis of 70-99 % operated in the 
medical group 
immediate surgery vs. waiting policy 
(incl. 1300mg aspirin/day) 
29 % operated in the waiting policy group 
immediate surgery vs. waiting poficy 
(incl. 1300mg aspirin and 75mg 
dipyridamole) 57 % operated in the waiting 
policy group 
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Veteran 167" 
ACAS29 
no symptoms at the side of the 
lesion 
no symptoms at the side of the 
lesion, in the vertebro-basilar 
system, or from the contralateral 
carotid territory within 45 days 
.. TIA, transient ischaemic attack 
t CEA, carotid endarterectomy 
, OPPG, ocular pneumoplethysmography 
0)10 0)10 PPV, positive predictive value 
t ICA, internal carotid artery 
§ TMB, transient moriocular blindness 
# eCA, common carotid artery 
ICA stenosis .2:. 50% 
ICA stenosis.2:. 60% on angiography 
or Doppler ultrasound with 95 % 
PPV'** 
or 90% PPV + positive OPPG 
CEA + 1300 mg aspirin vs. 1300 mg aspirin 
immediate surgery vs. no surgery 
325 rng aspirin + risk factor reduction in 
both groups 
5% operated on in the medical group 
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clons 'vere used: 
1 
-Jl{s'Cf --) 
0s(t) = 1- (1- 0s(1l11onth))· e 12 
Pranl this we have: 
IRs =-(In 1-CI,(t) )/(t-~) 
1- Cis (1111onth) 12 
equation 3 
equation 4 
where Glt), ell/lllolltb) and IR, denote the t-year and one month cumulative inci-
dence and the incidence rate from one month onwards, respectively, in the surgical 
group. 
For one trial the actual curves ,vere not given, but the estimates needed could be 
extracted by a standard actuarial methad.n 
If time to event curves were not provided, incidence rates were calculated as the 
number of strokes or deaths divided by the total person-years of follow-up 'at risk', 
The mean follo\v-up time ,vas usually not published separately for the study groups. 
To divide approxitnately the total amount of follo\v-up time over the two groups, 
we took the ratio of tile number of patients at risk at ti,e end of ti,e first monti, as 
the ratio of the amounts of follow-up titne after the first month in the two groups. 
If it was not stated otherwise, we assumed that the follow-up time given in each 
report c01'1'esponded to the time either until death or until censoring and in each 
trial patients ,vho sustained a non-fatal stroke have been followed until death or 
until censoring. Therefore the total person-years of follow-up reported minus half 
the mean follo,v-up for each patient ,vho had non-fatal stroke was taken as the 
denominator for the incidence rate extraction for the combined outcolne of stroke 
or death. 
Since no survival curves were reported for death from all causes for any trials, 
this latter method was used to estimate incidence rates of death, as well. 
The observed 3-year cumulative incidences of stroke or death were read off 
~rom stroke-free survival curves if the curves were published. \\lhen the curves \vere 
not given, trial-specific duee-year cumulative incidences of stroke or death were 
estimated from the incidence rates by exponential conversion (see "equation 1 and 
3"). 
Statistical methods for pooling 
To assess the relationship between the incidence rates of the events of interest from 
the first month onwards in the surgical and medical groups respectivel}~ a linear 
regression 1110dcl ,vas used. \\'e assumed that the measures of the disease frequen-
cies "observed" in the trials arc measured with some error due to sampling vari-
ability, and there are "ttue" underlying surgical risk and long term incidence rates of 
events both in the medical and surgical groups in each trial. 
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The following relationship between the "true" event rate tIRMi under the medical 
treatment in the ith trial and dIe "true" event rate tIRSi in the surgical group of dIe 
ith trial is assumed: 
In(tiRs,) = (/ + b ·In(tiR,\f') + ej equation 5 
where a and b are regression coefficients to be estimated and dIe error tenn ej is 
assumed to be normally distributed with zero lnean and unkno\vn standard devia-
tion. Note that this is a direct generalization of d,e standard random-effect approach 
in meta-analysis. If b := 1, then our model reduces to the well-known lllodel of 
DerSimonian and Laird.34 In fact the model assumes a bivariate normal distribution 
for the "uue" event rates in the two treatment groups) and is therefore identical 
to the bivariate random effects meta-analysis model described by van Houwelingen 
et al.35 The observed number of events in a treatment group of a trial is assumed 
to be Poisson distributed \vid1 mean equal the follo\v-up in person-years in that 
group lnultiplied by the "true" event rate in that group. Furthermore, in analogy 
with standard random effects models used for meta-analysis it was assunled dlat 
dIe logarithms of dIe "true" incidence rates of dIe medically treated groups were 
normally distributed with mean and variance to be estimated from d,e data. The 
model was fitted by a Bayesian analysis medlod analogous to tile medlOds described 
by Thompson et al. using Gibbs sampling by the program BUGS,"·20 but taking into 
consideration the comments of van Houwelingen and Senn.21 Throughout unin-
formative prior distributions were used. 
When the analysis showed d,at b was likely to be close to one (i.e. no evidence 
of "linear" heterogeneity of incidence rate ratios), this parameter was set to one in 
the model and a was recalculated. In this case the pooled estimate of tIR/ tIRM was 
taken as exp(a). When the analysis showed that b is likely to differ from one, both 
a and b \vere estimated and \vere considered as the result of the pooled analysis. In 
this case the itnplication of the analysis is that for any given value of fIRM the value 
of tIR, can be estimated as exp(a + b x In(tJR.,,)). 
For estimating the "true" three years cumulative incidence ratio for stroke or 
death as a function of the "true" incidence rate of stroke or deadl in the medical 
group (tlR,,), we extended the above-described bivariate model. In the extended 
model \ve assumed a trivariate normal distribution of the "true" log odds of stroke 
or death in the surgical group in the first month, of the "true" log incidence rate 
of stroke or deadl in d,e medical and in tile surgical group. After fitting the model 
for calculating the duee-year cumulative incidence ratios "equation '1 and 3" \vere 
applied. The model was fitted using d,e program BUGS employing a non-informa-
tive prior distribution on the unknown model parameters. The BUGS syntax for dllS 
problem can be obtained from the authors. 
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RESULTS 
Table 2 shows the observed surgical risks and incidence rates in the trials. The 
pooled estimate of the one-n10nth cumulative incidence of stroke or death in the 
surgical group obtained from the trivariate model was 6 percent (95 percent confi-
dence interval 4.8-7.5). 
The regression analysis of death rates yielded b = 1.21 (95 percent confidence 
interval 0.96-1.53). As this indicated that there was no evidence for b being differ-
ent from 1, the model was refitted as described above (see statistical methods for 
pooling). This yielded a In (incidence rate ratio) of a = -0.025 (95 percent confidence 
interval-O.B, 0.088). After exponentiating, the pooled incidence rate ratio for death 
becomes 0.98 (95 percent confidence interval 0.88-1.09). 
Pooled regression analysis of incidence rates of stroke or death yielded the fol-
lowing relationship between the incidence rates of stroke or death from the first 
month onwards: 
EOnIRsJ = 1.07 + 0.32 . In (IR",J, 
where IRSi and IR,ui stand for the trial-specific underlying "true" incidence rates in 
the surgical and medical arms, respectively. The 95 percent confidence interval of 
the intercept (0 in "equation 5") in the model was 0.18, 1.93 and of the slope (b 
in "equation 5") it ,vas -0.11-0.76. The latter indicates that there is evidence that 
the second parameter differs from one, so there is heterogeneity in incidence rate 
ratios between trials, and the parameter can therefore not be set to one in the model. 
The relationship between IRs and IRo\( suggested by the model is plotted in figure 1 
together with the 95 percent confidence interval. Observed values for each trial are 
also indicated. The figure shows that the effect of surgery on the incidence rate of 
stroke or death from the first month onwards increases with the incidence rate of 
death or stroke in a comparable patient treated medically. The figure also shows that 
the model fits the available data reasonably well) with two outliers) which originate 
from the very small trials of Shaw et al. and of Clagett et al.22•24 Omission of these 
trials does not influence the result. 
The relationship between the incidence rate of stroke or death in medically 
treated patients and the three-year cumulative incidence ratio of stroke or death 
comparing patients assigned to surgery with patients assigned to medical treatment 
is plotted in figure 2. Observed values are also plotted for each individual trial or 
trial subgroup. It can be seen that the acmal observations are well fitted by the func-
tional relationship. The figure shows that the break-even point, the value of the 
base-line incidence rate above which surgery is beneficial in regard the three-year 
risk of stroke or death is 7.7 strokes or deaths / 100 person-years (95% confidence 
interval 7.1, 8.3) if we apply the pooled estimate of the surgical risk. So above a 
baseline risk of 8.3 stroke or deaths / 100 person-years immediate surgery is signifi-
cantly better. 
Outcome: death Outcome: stroke or death 
Study Nsurg* Nm(ld't 
Cisurg , IRmed§ IRsurg' Cisurg IRm&d IRsurg 
Joint study 169 147 3.6 5.4 4.0 11.2 7.5 4.6 " Q 
Shaw et al. 20 21 15.0 5.1 12.3 35.0 13.8 17.5 < Q 
Veteran 309 91 98 3.3 5.5 9.3 6.3 ;? 
ECST 0-19% stenosis 78 62 1.3 3.2 4.4 6.4 4.4 5.1 g' 
ECST 20-29 % stenosis 162 117 0.6 4.2 4.8 1.9 5.7 6.2 So 
ECST 30-39 % stenosis 200 139 1.0 4.7 4.6 7.0 5.5 5.6 ~ 
ECST 40-49 % stenosis 190 122 1 .1 3.2 4.0 9.5 4.4 4.3 0 A" 
ECST 50-59% stenosis 350 240 1 .1 4.5 4.4 6.3 6.1 5.2 Q 
ECST 60-69% stenosis 232 137 2.2 3.8 3.9 9.5 6.1 4.5 0--< 
ECST 70-79% stenosis 231 170 1.7 4.9 4.4 9.1 7.0 5.2 0 rn 
ECST 80-89% stenosis 251 159 0.4 4.9 5.1 4.8 7.9 5.9 §. 
ECST 90- % stenosis 113 65 1.8 4.8 5.5 4.4 10.0 5.8 c: 
NASCET < 50% stenosis 678 690 1.2' 2.0 1.8 6.6' 6.7 5.3 rn ~ NASCET 50-69% stenosis 430 428 1.2' 2.4 1.9 6.6' 8.3 4.7 9; 
NASCET 70- % stenosis 328 331 0.6 4.0 2.8 5.8 16.3 5.3 
" Clagett et al. 15 14 0 2.2 7.3 0 2.2 7.3 m 0 
CASANOVA 206 204 1.5 6.8 6.4 3.4 10.8 9.3 0" 
Veteran 167 211 233 1.9 7.8 7.9 4.3 9.9 8.0 ~ 
ACAS 825 834 0.5 3.9 3.7 2.7 7.0 5.3 
.. Nsurs, number of subjects in the surgical groups 
t NmOd, number of subjects in the medical group 
:t: Cillurs, cumulative incidence in the surgical group (%) 
§ ,1Rmod , ",observed" in-cfdence rate (number of events' I 1-00 person-years)' in the medical' group fro'm randomization 'onwards 
, IRsurg, "observed" incidence rate (number of events J 100 person-years) in the surgical group from the first month onwards 
# estimates Courd be calculated only for the two subgroups combined Ol 
-oJ 
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5 10 
number of strokes or deaths I 100 person-years 
INCIDENCE RATES IN THE MEDICAL GROUP 
• 
15 20 
Relationship between incidence rates of stroke or death in the medical and in the 
surgical group, estimated regression line with its 95 % confidence interval. Dotted 
line is the line of equality. Observed data from the trials are indicated with •. Values 
are plotted on logarithmic scales. 
DISCUSSION 
The aim of this meta-analysis was to assess the safety and long-term efficacy of 
the surgical treatment of carotid artery stenosis in comparison to medical treat-
ment alone. Our pre-specified choice of parameters followed directly from trus aim. 
When the individual patient data from tl,e trials are not available, one is entirely 
dependent on the way data is reported. As there is no uniform approach to the latter, 
the parameters chosen to be of interest in a meta-analysis are often not reported 
as such but have to be estimated based on the original reports. In tIlls regard tI,e 
current meta-analysis is no exception. The individual data were not available and the 
parameters of interest chosen had to be estimated from published data. In doing so, 
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number of strokes or deaths I 1 00 person~years 
INCIDENCE RATE DF STROKE OR DEATH IN THE MEDICAL GROUP 
18 
Relationship between the incidence rate of stroke or death in the medical group and 
the three-year cumulative incidence ratio of stroke or death surgical versus medical 
group. Observed data from the trials are indicated with •. Continuous lines indicate 
the pooled estimate of the cumulative incidence ratio with its 95 % confidence 
interval as a function of the incidence rate in the medical group. 
several assumptions had to be made. 
First of all, we assumed that the incidence rates of death, and of stroke or death 
are constant in the medical group from the moment of randomization onwards and 
in the surgical group after the first month, Tlus assumption is reasonable because 
carotid artery stenosis with or without symptoms is a chronic condition. Generally, 
the degree of stenosis ,,,ill progress with time and in the long run therefore the 
incidence rates will increase. However, over a three-year period the increase should 
be small indeed, if detectable at all in data of the type considered, In many trials 
or trial subgroups considered the mean follow-up ,vas shorter than four years. \,Te 
focused on the three-year outcome because over dus relatively short period of time 
the incidence rates should be approximately constant and because we wanted to 
avoid extrapolation beyond the follow-up period of the majority of patients, 
Secondly, ,ve assumed that the person-years of follow-up after the first tllonth in 
the surgical and medical groups respecti\iely can be approximated as described from 
the total follow-up for both groups combined and from the number of subjects 
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at risk after the first month in each group. In most cases this assumption is neces-
sary because the amount of follow-up is not reported by treatment group. For low 
incidence tates that do not differ too much, this seems to be a reasonable assump-
tion. In this context, we also assumed that the amount of follo,v-up until stroke or 
death can be approximated from the amount of follow-up until death as described. 
Although participation in some trials was restricted to surgical teams who could 
show that their complication tate was acccptable,26,36.3B our cscitnate of surgical risk 
is consistent with the reported results from other studies.39-4-t In clinical practice the 
risk of angiography must be considered also.45,46 Nevertheless, one can easily plot 
the curve on figure 2 for different values of the surgical risk applying "equation 1, 
3 and 5". 
Regarding the long-term effect, it is entirely possible that surgery offers a greater 
advantage in patients who are at a higher absolute risk of stroke when treated medi-
cally. As a consequence, measures of effect mal' differ from trial to trial depending 
on the underlying risk of the patients actually randollllsedY In a meta-analysis a 
measure of effect (such as the 'odds ratio') is usually pre-specified and the question 
whether heterogeneity exists for the chosen effect measure is addressed by the so-
called heterogeneity test." Tlus approach has at least two disadvantages. First of all, 
the power of the heterogeneity test is Imv.48 Second, the method does not specify 
how to continue the analysis when the heterogeneity test is 'sigrlificant'. Hence, 'a 
preferable statistical method allows for the possibility that effects are heterogene-
ous. Based on published data, such a method should provide an estimate of the 
treatment effect conditional on some trial characteristics, such as aggregate infor-
mation of subjects included or risk in the reference category. One method that 
acc01nplishes tIlls has been used prcviously to describe tIle expected mortality rate 
of patients treated for hypertension given the rate in the absence of treattnent.49 
That method was based on a weighted linear regression of the observed event rates 
in the treatment group against tIle observed evcnt rates in the control group. It may 
produce biased estimates due to imprecision of tlle observed incidence rates used as 
independent variable in fitting the model,50 The method used in tillS analysis avoids 
tllls problctp., because the estimated "true" incidence rates in the control groups is 
used as independent variable. 
\Xlith respect to long-tenn efficacy, our analysis suggests that surgery does not 
increase life expectancy. The reason for this is the initial risk of complications. Even 
if the operation ,vas completely safe, the reduction in mortality would be nlodest as 
the incidence rate ratio of death after ti,e first month comparing surgery to medi-
cal treatment is 0.98. A possible explanation is that carotid artery stenosis mal' just 
be onc manifestation of generalized atllerosclerosis which also affects other parts 
of ti,e vascular system. A reflection of tillS is that only a minor proportion of 
deatlls attributable to cardiovascular disease is due to stroke. Furthermore, only a 
fraction of strokes are related to carotid artery stenosis. Hence, the potential itnpact 
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of carotid endarterectomy on all cause mortality must be limited. 
Nonetheless, our analysis shows that surgery can be expected to prolong stroke-
free survival provided that the procedure is limited to patients who have a relatively 
high risk of stroke due to carotid stenosis. Pigure 1 compares observed incidence 
rates in the medically treated patients ,vith the incidence rate in those surgically 
treated patients who survive the first month after surgery without a stroke. It shows 
that patients at low risk of stroke or death when treated medically are unlikely to 
benefit from surgery. \\lith increasing risk, surgery becomes lnore effective relative 
to medical treattnent. Since we neglected the first month after surgery in figure 1, 
to compare the treattnents fairly we estimated the 3-year cumulative incidence of 
stroke or death, taking into account the surgical risk, and then comparing both treat-
lllent options. As is shown in figure 2, surgery is beneficial only when the estimated 
incidence rate of stroke or death for medical treattnent is above about 8.3 strokes or 
deaths / 100 person-years. With increasing risk of stroke or death for medical treat-
ment, surgery becomes more effective. A possible explanation is that at lower risks 
there are simply too few events that can be prevented by surgery. Hence, its risks 
predominate. The break-even point above which surgery becomes effective could be 
a useful guideline in clinical practice if it were possible to estimate the incidence rate 
of stroke or death in an individual patient before taking the decision to operate. 1\ 
multivariate risk function for identifying patients within the group of subjects with 
70-99 percent carotid artery stenosis who are at high risk of stroke on medical treat-
ment and are at low risk of operative stroke or death has recently been published 
from ti,e ECST study.51 Preoperative risk factors of carotid endarterectomy have 
also been reported. Some patient characteristics playa role, but one of the most 
important factor seems to be the surgeon.40•41 ,S2 
Naturally, one of ti,e most powerful predictors of stroke is the degree of carotid 
stenosis. Several studies and the trials analyzed in tlus report have shown that tlle 
higher ti,e degree of the stenosis, the higher the risk of stroke. In addition, given a 
certain anatomical degree of stenosis, symptomatic patients have worse prognosis 
than those Witll0ut symptoms.25,32,33,5.j-S8 In patients on medical treaUnent with severe 
symptomatic anatomic stenosis, i.e. more than 700/0 according to the NASCET cri-
teria the average incidence rate of stroke or death is higher than ti,e 8.3 per 100 
patient_years.2S,32,53,59 Hence, in these patients surgery is indicated based on tlle results 
of tlus analysis. In patients with a moderate sytnptomatic or severe asymptomatic 
stenosis tlle incidence rate is around the range (7.1, 8.3) where it is not clear wluch 
treatment is better.27,29,31-33,S3-S7 Hence, these patients may benefit ftom surgery if they 
are operated ,vith very low complication rate. Several features have been reported 
that might help identifying high risk subjects in tills category of stenosis, like con-
tralateral disease, impaired cerebral vasomotor reactivity, asynlptomatic emboliza-
tion, and echostructure appearance of tlle carotid plaque.5s.62 For lower risk patients, 
i.e. under 7.1 stroke or death per 100 patient-years, surgery should even be consid-
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ered as harmful. Based on ~he results available today and this meta-analysis, a \vaiting 
policy in these patients is indicated. This policy should include clinical follow-up and 
non-invasive assessment of the lesion to determine whether the patient remains at 
low risk. If this docs not seem to be the casc, surgery can then be offered. 
\1'e conclude that carotid endarterectomy is a relatively safe procedure which 
prolongs stroke-free survival in patients with a high risk of stroke or death. For 
moderate or lov,T risk patients, there is at present no evidence that supports that such 
patients should be operated also. 
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Change in a risk factor as a 
determinant of disease. 
The pitfall of 
adjustment for baseline 
III stl/dies cf the relatiollship betmeen challge ill a J1sk farlor and the ocmrrence 0/ (/ disease, the 
baselille ,'alm of the fisk fador is 1IS1f(1I!), (ollSidmd as a potelltial COIl[olflldCl: Thmji'" it is oftell 
adjlfsled [or ill the alla!)'ses. HoweveI; be((lllse of the pheJIOIlJeIlOIl of regressioll IO/pards Ihe meall 
adjlfstmeJIt [or baselille Iwei/llfI)' ((Illse sellm bias. 011 the other halld, re[millillgji'oll/ adjllslmeJIt 
ill 11/(111)' illsiallteS prodlfces /fIlbiased or 011// slightly biased mlilts. 1J7ith all estimate of the witbill 
sllbjects ,'miability (/II IIlIbiased estimate of the ~fle(/ of challge rail be ob/m;"d IIsillg hiem/'{hiral 
modellillg. II is ",peeted th({tmethods based 011 hiemrchical models that ((III deal stmightjiml'flrdl/ 
u,;th II/MSI/rell/ent errorproblell/s like this lJ!ill be atJai/ab/e for rol/h'lle lise soon. If {III Jlllbiased 
estimate of the challge rail 1I0t be obltiilled, it is beller 110110 adjllst for baselim 1I(lIl1e of the fisk 
jacto/: 
I n an increasing number of studies risk factors are measured at several points in time. A question dlat is often addressed in these studies is ,vhether change in a risk factor over titne is associated widl disease outcome. In a clinical setting, 
for example, one could investigate dIe association between change in a nlonitored 
physiological parameter and a certain outcotne. In cohort studies where repeated 
exposure assessment is carried out, one might want to study the relation between 
change in exposure status and occurrence of disease. 
In most of these studies the baseline level of the risk factor is considered a con-
founder of the relation between change in the risk factor and the risk of the disease. 
Therefore it is usually adjusted for or stratified on in dIe analyses, and nlost of the 
authors do not present the results without adjusttnent for baseline. l -s Although this 
practice seems to be appropriate at first sight, it is incorrect. In dus paper we show 
why this method produces biased results, illustrated with an example taken from tbe 
Rotterdam Study, and discuss potential solutions. 
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melhod 
adjustment for baseline 
no adjustment for baseline 
Chapter 9 
odds ralio' (95% ell 
1.10 (1.00; 1.22) 
1.00 (0.91; 1.10) 
.. Corresponding to 10 mmHg increase in blood pressure. Adjusted for age and gender. 
CI: confidence interval. 
WHY DOES CURRENT PRACTICE PRODUCE BIASED 
RESULTS? 
We wanted to study the relationship between change in systolic blood pressure and 
the risk of stroke in the Rotterdam Study, which is a prospective population based 
cohort study among 7983 subjects, aged 55 years or over, li\.ing in a suburb of Rot-
terdam, The Netherlands. The rationale and design of the Rotterdam Study have 
been described elsewhere.' Baseline examinations took place in 1990-1993 and fol-
low-up examinations in 1993-1994, and 1997-1999. In addition, the cohort is con-
tinuously being monitored for major disease Qutc01IlCS, including stroke. Subjects 
were included in the analysis if they had blood pressure measurements at both the 
baseline and first follow-up examination, and \vere free from stroke at the dnle of 
first follow-up. The risk of stroke associated with change in blood pressure was 
estimated by calculating odds ratios through logistic regression with adjustment for 
age and gender. 
High systolic blood pressure itself is a known risk factor for stroke. If change in 
systolic blood pressure depends on the baseline value, baseline systolic blood pres-
sure would be a potential confounder) l.e. any observed association between change 
in systolic blood pressure and risk of stroke might result in whole or in part from the 
relation between the baseline systolic blood pressure and stroke. Following standard 
methods to deal with confounders, we adjusted f01" baseline systolic blood pressure 
in the analysis. The result is presented in Table L Based on tlus we would conclude 
that there is evidence that an increase in systolic blood pressure increases the risk of 
stroke. 
What if we consider tI,at baseline value of systolic blood pressure is not related 
to change? In that casc, baseline systolic blood pressure would not be a confounder 
and there would be no need to adjust for it in ti,e analysis. Table I presents the result 
without adjustment for baseline systolic blood pressure, too. This does not provide 
evidence for an association between change in systolic blood pressure and risk of 
stroke. 
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WHICH ANALYSIS IS CORRECT? 
At first sight it seems that the analysis with adjustment for the baseline value of 
systolic blood pressU1'e must be the correct one. The population distribution of 
systolic blood pressure consists of individual distributions, with their mean repre-
senting the individuals typical or "true" value. 10 A single measurement may be higher 
01' lower than the individual's actual typical value. This is due to either biological 
within subject variability, or to measurement error, or usually to bothY·12If we take a 
second measurement in a subject it is more likely that it ,vill be closer to the individu-
al's typical value.1O As a consequence, if we select a group with extreme observed 
baseline blood pressure, their group mean of the second nleasurement will be closer 
to the population mean. 13,14 The phenomenon is called regressioll tOJPards the meal/. J3 
How IS THIS PHENOMENON RELATED TO ADJUSTMENT 
FOR BASELINE? 
Figure 1 illustrates the situation ,,,hen the typical value (hereafter "true" value) of 
systolic blood pressure remains unchanged in every subject, meaning "true" change 
is zero. Nevertheless, even in this situation the observed value ,vill change in most 
of the individuals. Let us examine in this situation what happens if ,ve adjust for 
baseline. 
When we adjust for the baseline level, we compare the risk of those subjects 
who had the same observed baseline blood pressU1'e. Figure 1 shows the individual 
distributions of two subjects with observed baseline systolic blood pressure of 110 
nllnHg. It can be seen that in the subject whose "true" blood pressure was higher 
than 110 InnlHg blood pressure will increase towards the ov,rn "true" value, and in the 
other subject whose "true" blood pressure was lower than 110 mmHg it will decrease 
towards the own "true" value. As a consequence, if we compare the risk of stroke in 
subjects whose observed blood pressure increased and those whose decreased, then 
,ve compare the risk of subjects whose "true" baseline blood pressure was high to 
those whose "true" baseline blood pressure was low. Those who had a higher "true" 
blood pressure at baseline are of course at a higher risk for stroke and we would 
conclude that an increase in systolic blood pressure increases the risk for stroke. It 
should be emphasised that the observed association hetween change in blood pres-
sure and risk of stroke in this case is not reflecting a true association, but a statistical 
phenomenon. 
Since all standard methods for controlling confounding - stratification, stand-
ardisation 01' regression analysis - are based on the idea of comparing the risk of 
subjects conditionally on d,e value of the potential confounder, they lead to d,e 
same bias. The bias will arise regardless whether we categorise change or use it as a 
continuous variable in the statistical model. 
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First follow-up examination 
distribution of blood pressure in a subject with a typical value of 120 mmHg 
distribution of blood pressure in a subject with a typical value of 90 mmHg 
• observed baseline systolic blood pressure 
50 70 90 110 130 150 170 
Systolic blood pressure (mmHg) 
Baseline examination 
Figure 1 
Illustration of the effect of adjustment for baseline systolic blood pressure. The 
direction of change is illustrated by the arrows. 
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In many instances "true" change is not zero and is associated ,,,ith baseline. In 
this case adjustment for baseline introduces bias as well, for the same reason that was 
discussed above. No adjustment also fails, since the estimated risk is not adjusted for 
confounding, caused by the relationship between baseline value and "true" change. 
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WHAT IS THE SOLUTION? 
First, as discussed above we should realise that adjustment for baseline value almost 
always results in severely biased estimates, since it is based on the assumption that 
observed change is equal to the change of the individual's H true" value. And this 
assumption is almost ahvays false, because of the regression towards the mean phe-
nomenon. 
Not adjusting for baseline can also cause bias if baseline value is associated ,vith 
H true" change. Nevertheless, in many instances the variance of the change due to 
regression to,vards the mean is large compared to the variance of the H true" change, 
e.g. when a physiological parameter has large biological within-subject variability, 
or in case of imprecise measurements. Furthermore, "true" change is often only 
weakly associated with baseline value. In these cases adjustment causes severe bias, 
while no adjustment for baseline leads to only slightly biased effect estimate. There-
fore, when the choice is between adjusting or not-adjusting for baseline, not adjust-
ing is tl,e recommended approach. 
The most appropriate analysis is based on the separation of the variance of 
change into the variance of H true" change and of the change due to regression 
towards the mean. The latter can be estimated by measuring the risk factor repeat-
edly and shortly apart.15 
Once one has an estimate of this variance, it becomes possible to estinlate the 
effect of "true" change. \Vith the use of an estimate of tIus variance of the "error", 
a solution for estimating the effect of the H true" change was proposed by Cain et at 
for linear and logistic regression analysis. 16 
Another solution would be directly estimating the effect of "true" change. Metll-
ods based on hierarchical models and simulation techruques can deal straightfor-
wardly with problems like this. Since these have bec01ne available recently, it is 
expected tllat unbiased methods to estimate the effect of change on outcome param-
eters will be available for routine use in the near futureY 
In our example blood pressure was measured again in 100 patients at a second 
visit two weeks later. Fr01n these measurements we estimated the ,vitlun-subject 
variability to be 116.6 mmHg". With the application of the metllOd suggested by 
Cain et al. we found no evidence that change in systolic blood pressure was associ-
ated with tl,e risk of stroke (p = 0.3). Tills is in contrast to the analysis witll sinlple 
adjustment for baseline. 
CONCLUSION 
The current approach - adjustment for baseline value of the risk factor - in stud-
ies of the association between change in a risk factor and disease produces strongly 
biased results because of the phenomenon of regression towards the mean. \'?e 
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illustrated the problem with an example from a cohort study. 
The larger the effect of the regression towards the mean and the weaker the 
association between baseline and "true" change, the less we gain from adjustment 
for baseline and the more harm we do. Therefore in many instances no adjustment 
for baseline is the recommended simple approach of the analysis, which leads to 
only slightly biased effect estimate. 
With the use of an estimate of the witltin-subject variability of the risk factor 
one can correct for the effect of regression towards the mean in the analysis. It is 
expected that unbiased metllOds based on ltierarchical models tl,at can deal straight-
forwardly w1th measurement error problems like this will be available for routine use 
soon to estimate the effect of change.17 
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General discussion 
T his thesis describes investigations related to the etiology and prevention of stroke. \\/e attempted to answer the following questions: 
Can we predict the probability of stroke based on the presence of major stroke 
risk factors? 
How is blood pressure related to stroke? 
• \\!hat may explain the controversial results about the relationship between serum 
cholesterol and the risk of stroke? 
• Is there familial aggregation of stroke? 
• Can dietary antioxidants prevent stroke? 
Is the use of aspirin for primary prevention of stroke jusrifiable? 
• How effective and safe is carotid endarterectomy in prevention of stroke? 
In the previous chapters studies aiming to answer these questions were presented .in 
details. In tlus chapter, I first surrunarise ti,e main findings and their interpretation 
and potential implications. A separate section is devoted to ne,v analytical methods 
we used in our studies. Next, I discuss major issues on the validity of the studies. I 
conclude with a brief outline summary of possible future directions for epidenlio-
logical research on etiology of stroke and envisaged short-term developments in 
research methods. 
MAIN FINDINGS 
All our studies, except the meta-analysis on the efficacy of carotid endarterectomy .in 
the prevention of stroke, were based on the Rotterdam Study, an ongojng prospec-
tive population-based cohort study for which all inhabitants aged 55 years or ovef, 
living in a suburb of Rotterdam, The Netherlands, were invited. Baseline data col-
lection was performed between 1990 and 1993. In total 7983 subjects participated 
(response rate 78%). Of these, 7603 subjects participated at the baseline interview 
and examination, and reported no previous stroke at baseline. Till the end of 1996 
346 strokes occurred among mem, the mean follow-up time was 4.46 years. 
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Risk and prevention of stroke 
Call JIle predict the probabilit), if stroke based 011 the pmellce if megor stroke Jisk 
factors? 
We validated the Framingham stroke risk profile within the Rotterdam Study. Risk 
factors included in the profile \vcrc age, systolic blood pressure, use of antihyperten-
sive therapy, diabetes mellitus, cigarette smoking, prior cardiovascular disease, atrial 
fibrillation, and left ventricular hypertrophy by electrocardiogram. Separate func-
tions were used for men and women. 
\'lIe estimated the three-year probability of stroke in 4930 subjects. We assessed 
how the profile estimated the number of strokes and TrAs that occurred within 
three years of follow-up and how the function could discriminate between high and 
low risk subjects. The estimated probability had a wide range; and the prevalence of 
the event was faidy well predicted in most categories of the estimated risk. 
The function discriminated equally regardless whether stroke or stroke and 11/\ 
wcrc considered as event. For stroke the area under the ROC curve was 0.75. 
Whether this performance is considered bad or good depends on the actual context 
in which the function is used. Since usually risk functions are used to identify high 
risk subjects, reasonably high sensitivity is required. \Vhcn the function is used as a 
screening instrument and additional diagnostic investigations are necessary to indi-
cate an intervention, very high specificity is not an inclispensable requirement. 
HOJl! is blood presSJlre related to stroke? 
The risk of first-ever stroke was associated with hypertension (relative risk 1.6,95% 
CI 1.2-2.0), and with isolated systolic hypertension (relative risk 1.7, 95% CI 1.1-2.6). 
\Yie found a continuous increase in stroke incidence with increasing blood pressure 
in non-treated subjects. In treated subjects we found a J-shapcd relation between 
blood pressure and the risk of stroke. The increased stroke risk in the lowest strata 
of blood pressure in treated hypertensive patients may indicate that the therapeutic 
goal "the lower the better" is not the optimal strategy in the elderly. 
Advanced atherosclerosis, or an excess of subjects with isolated hypertension 
among subjects with very low diastolic blood pressure could not explain our finding. 
We assume that since chronic hypertension shifts the lower and upper blood pres-
sure limits of cerebral blood flow autoregulation to\vards higher pressure, it makes 
the brain more susceptible to ischemia at low blood pressure. 
We should emphasise that treatment of elderly hypertensive subjects has been 
proven to safe lives, to prevent myocardial infarctions and strokes, and our findings 
do not contradict these findings. Our results showed that in treated hypertensive 
elderly subjects only very low diastolic blood pressures increased the risk of stroke. 
One might consider that a blood pressure below 65 mmHg is rarely a target 
blood pressure in everyday practice and that an increased risk associated with very 
low blood pressure is merely a dleoretical problem. Ho\vever, 20 percent of the 
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antihypertensive drug users in tills elderly population fell into that category. 
1l7h{lt l"fI)' e.'P/aill the cOlltrO/Jers;a/ reslI/ts abollt the I~/at;ollship befllleell senll" 
cho/estem/ alld the /isk of stroke? 
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Clinical trials with I-l1vlG-CoA reductase inhibitors have shown a 30 percent reduc-
tion in the risk of stroke by these drugs. On the other hand, observational studies 
have provided controversial results about the relationship between serum cholesterol 
and the risk of stroke. Some confirm that cholesterol increases the risk of stroke, 
but the bulk of the evidence points to no relation. Although statins may have other 
beneficial effects than cholesterol lowering which may partly explain their effect, we 
thought that this apparent paradox needed further explanation. 
In the total study population we found no relationship. However, high serum 
cholesterol level significantly increased the risk of ischemic stroke in subjects who 
were free fronl cardiovascular diseases and diabetes mellitus (highest quartile versus 
lowest quartile, relative risk 2.3; 95% CI 1.2-4.4). The ratio of serum total choles-
terol and lllgh density lipoprotein cholesterol was associated with the risk of stroke 
neither in the total study population nor in subjects free from cardiovascular diseases 
and diabetes mellitus. 
Several methodological difficulties have to be addressed when weighing and con-
sidering available results about the relationship between serum cholesterol level and 
the occurrence of stroke. Some of the most important ones are the following: 
Since low cholesterol level is associated with hemorrhagic stroke, studies in which 
any stroke is the outcome are unlikely to demonstrate increased stroke risk \vith high 
cholesterolleve!. TillS is even less likely when fatal stroke is considered as tl,e out-
come, since the case-fatality rate of hemorrhagic strokes is higher, thus their propor-
tion is higher among fatal strokes than among any strokes. 
Stroke may alter serum lipid levels, therefore case-control studies may lead to 
biased results if lipid levels measured immediately after stroke are used in the analy-
sis. 
lvIost studies did not control for coronary heart disease. Since the association 
behveen high serum cholesterol level and coronary heart disease is already known 
for almost four decades, patients suffering from coronary heart disease are likely to 
change their diet or use lipid-lowering drugs, and consequently reduce their serum 
cholesterol level. Indeed, in our study those subjects who suffered frotn cardio-
vascular diseases \vere more likely to start using lipid lowering drugs. Presence of 
cardiovascular diseases increases the risk of stroke, and tIus may result in an under-
estimation of the true risk associated with elevated cholesterol, as illustrated with 
our findings. 
Our study supports the view that high serum cholesterol is a risk factor for 
ischemic stroke. 
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Is there falllilia! aggregatioll of stroke? 
Available evidence suggests tbat family history of stroke increased the risk of stroke, 
but it is unclear whether this risk depends on the age of the proband, the kind or 
number of family member(s) affected, or the age at stroke in the relative. Further-
tll0rC, it is unclear whether the risk of stroke is also increased for persons with a 
positive family history of myocardial infarction. 
We found that a history of stroke in any first degree relative significantly increased 
the risk of stroke (relative risk 1.3; 95% CI 1.0-1.6). The risk was even higher for 
persons who had more than one relative ''lith history of stroke Of a Hrst degree 
relative who suffered from a stroke before the age of 65. Family history of early 
myocardial infarction also increased the risk of stroke, albeit not statistically signifi-
cantly. 
Our findings suggest tl,at genetic susceptibility does playa role in the etiology 
of stroke, altllough overall familial aggregation seems to be modest. Genetic factors 
appear ll10re important in early onset forms of the disease. 
Call dieta!), alltioxidallts pl~liellt stroke? 
Oxidative stress reportedly plays a role in the etiology of stroke. Therefore dietary 
intake of antioxidants might lower the risk of stroke. High intake of fruits has been 
reported to protect against stroke. Free radical activity is higher in smokers, and it is 
reflected in the higher level of free radical activity mediated lipid peroxidation prod-
ucts in their blood. Our aim was to shldy in tl,e Rotterdam Study the relationship 
between dietary flavonoids, antioxidant vitamins, selenium and the risk of stroke 
and to investigate wl~ether the effect of these antioxidants is different in smokers 
and non-smokers. 
Higher intake of vitamin C, p-carotene and selenium was associated ,vith a lower 
risk of stroke in the total shldy population. After stratification for smoking behav-
iour it became apparent that this protective effect was only present in smokers. Con-
sumption of fruits and flavonoids also considerably decreased the risk of stroke in 
smokers, altllOugh the latter did not reach statistical significance. Intake of vegeta-
bles and vitamin E was not associated with the risk of stroke. 
Our findings indicate tl,at high intake of vitamin C, p-carotcnc and selenium can 
be a useful method in stroke prevention, especially effective in smokers. 
Is the role of aspilill ill Plilllal]' prellClltioll of stroke jllstijiable? 
The role of aspirin in primary stroke prevention is not dear. Two large clinical trials 
and a tneta-analysis have suggested that aspirin may increase the risk of stroke, in 
particular hemorrhagic stroke, in low risk subjects, but tIlis finding was not statisti-
cally significant. Recently it was reported from the Cardiovascular Healtll Shldy that 
aspirin use increased the risk of stt'oke in elderly women free from cardiovascular 
diseases. 
In the total cohort of the Rotterdam Study there was a weak, non-significant 
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association between aspirin use and the risk of any stroke. In subjects without vas-
cular diseases aspirin use was associated with the risk of stroke (RR 1.80; 95% CI 
1.03-3.13). In these subjects the risk of ischemic stroke increased as well, albeit less 
than the risk of all strokes, and not statistically significantly. Among subjects Witll 
vascular disease there was no association behveen aspirin use and the risk of stroke 
(RR 0.99; 95% CI 0.56-1.73). 
The possibility of an increase in the incidence of hemorrhagic stroke in aspirin 
users is not unexpected. But in addition, aspirin may have a paradoxical thrombo-
genic effect, probably by inhibition of PGI2 production in endothelial cells and 
by inhibiting ti,e expression of ti,e inducible nitric oxide syntllase. If aspirin has a 
thrombotic side effect, it is expected to be detected in subjects who have very little 
to gain from its beneficial effect, i.e. in subjects \vithout vascular disease. 
It seems necessary to further study the role of aspirin in primary prevention. 
These studies should address ti,e effect of aspirin on all major vascular events -
stroke, tnyocardial infarction, and death - to study the net effect of aspirin use in 
primary prevention. Even if the net effect were beneficial considering all benefits 
and harms of aspirin use, it might be possible to identify subgroups of subjects who 
gain and who lose \vith the use of aspirin in prevention of cardiovascular diseases. 
HOII'iffoctive tllld safe is ctlrotid elldtll1enctolll)' ill pretlClltioll of stroke? 
It is estimated that 20-30 percent of stroke cases is related to carotid artery stenosis. 
Carotid endarterectomy aims to remove the plaque and restore the lumen of the 
vessel. Although the first published operation \vas carried out decades ago and more 
tI,an 1 million people have been operated since 1980 in the United States only, there 
are still unanswered questions regarding the efficacy of carotid endarterectomy in 
the prevention of cerebral infarction and death. We performed a meta-analysis to 
assess the effect of carotid endarterectomy on all-cause tnortality and stroke-free 
survival based on the combined data from randomized trials. 
WTith respect to long-term efficacy, our analysis suggests that surgery does not 
increase Hfe expectancy. The reason for this is the initial risk of complications. Even 
if the operation were completely safe, the reduction in mortality would be modest as 
the incidence rate ratio of death after the first month comparing surgery to medical 
treatment is 0.98 (95% CI 0.88-1.09). On ti,e other hand, carotid endarterectomy can 
prolong stroke-free survival. This beneficial effect after three years of operation is 
present only when the estimated incidence rate of stroke or death in patient receiv-
ing only medical treatment is above about 8.3 per 100 patient-years. With increasing 
risk of stroke or death surgery becomes more effective. 
Based on our analysis carotid endarterectomy should only be considered for 
patients at high risk of stroke. The break-even point abovc which surgery becomes 
effective could be a useful guideline in clinical practice if it were possible to estimate 
the incidence rate of stroke or death in an individual patient before taking the deci-
sion to operate. 
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One of tile most powerful predictors of stroke is the degree of carotid stenosis. 
In patients on medical treatment with severe symptomatic anatomic stenosis the 
average incidence rate of stroke or death is higher than the break-even point. In 
these patients surgery is indicated based on the results of this analysis. In patients 
with a moderate symptomatic or severe asymptomatic stenosis the incidence rate is 
around the range where it is not clear ,vhich treatment is better. These patients may 
benefit fronl surgery if they are operated with a very low complication rate or are 
at higher risk for stroke than the average of this group. Several features have been 
reported that might help identifying high risk subjects in this category of stenosis, 
including contralateral disease, impaired cerebral vasomotor reactivity, asymptomatic 
embolisation, and cchostructurc appearance of the carotid plaque. In subjects widl 
less than moderate symptomatic stenosis surgery should even be considered harm-
ful. Based on our tneta-analysis, in these patients a waiting policy is indicated. Tius 
policy should include clinical follow-up and non-invasive assessment of the lesion 
to determine \vhether the patient remains at low risk. \X!hen the estimated risk of 
stroke increases, surgery can be offered. 
New methods 
A Bayesiall I'fIlldolll effect /lJeta-allaD'sis 
In a meta-analysis a measure of effect (such as the risk 01' rate ratio) is usually pre-
specified and the question whether heterogeneity exists for the chosen effect meas-
ure is addressed by the so-called heterogeneity test. This approach has at least two 
disadvantages. First, the po\ver of the heterogeneity test is low. Second, the method 
does not specify what to do when the heterogeneity test is 'significane. A statistical 
method d,at allows for heterogeneity of effects is preferable. Such a method should 
provide an estimate of the treatment effect conditional on certain trial character-
istics, such as aggregate information of subjects included or risk in the reference 
category. 
Regarding d,e long-term effect of carotid endarterectomy, it is entirely possible 
that surgery offers a greater advantage in patients who are at a higher absolute 
risk of stroke when treated medically; As a consequence, measures of effect may 
differ from trial to trial depending on the underlying risk of the patients actually ran-
domised. "Ie wanted to estimate the effect of carotid endarterectomy conditional on 
the risk of subjects treated medically. Conventional methods used for the anall'sis of 
this type of data may produce biased estimates due to imprecision of the observed 
incidence rates used as independent variable in fitting the model. The method we 
developed avoids this problem, because the estimated "true" incidence rates in the 
control groups is used as independent variable. In our final model, where \ve esti-
mated the three-year cumulative incidence ratio of stroke 01' death, we assumed a 
trivariate normal distribution of the "true" log odds of stroke or death in the surgi-
cal group in the first month, of the "true" log incidence rate of stroke or death in 
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the medical and in the surgical group. The model was fitted using Gibbs sampling 
by the program BUGS. 
S!lIdj'illg challge ill a Jisk factor as a de!en/lillall! of disease 
In an increasing number of studies risk factors are measured at several points in 
tinle. A 'luestion that is often addressed in these studies is whether change in a risk 
factor over time is associated with disease. 
In most of these studies the baseline level of the risk factor is considered a con-
founder of the relationship between change in the risk factor and the risk of the 
disease, therefore it is adjusted for or stratified on in the analyses. We showed that 
this practice may produce severely biased results, because of the regression towards 
the mean phenomenon. 
\Ve argue that refraining frot11 adjustment in many instances produces unbiased 
or only slightly biased results. With an estimate of the within subjects variability 
unbiased estinlate of the effect of change can be obtained using hierarchical model-
ling. It is expected that methods based on hierarchical models that can deal straight-
forwardly with the problem will be available for routine use soon. 
VALIDITY 
An etiologic investigation can be conceptualised as a measurement device that alms 
to estimate an association measure, usually a relative risk. Just like in any other meas-
urement exercise it is important to avoid systematic bias and randonl errors. The 
former issue is discussed under validity, the latter one under precision. 
Precision of the effect estinlate in epidemiologic research is directly related to 
the size of ti,e study. The precision of the effect estimates is quantified by tI,eir 
confidence intervals. 
There are three tnajor threats for validity in etiologic research: selection bias, 
infonnation bias, and confounding. 
Selection bias 
Selection bias occurs when selection of subjects is not independent from the occur-
rence relation under study. This means that the association observed in the study is 
different from tllat would bave been observed in tl,e source population. One poten-
tial reason in our studies for this kind of bias was non-response, since not all eligible 
subjects participated. Although those who did not participate were likely to be dif-
ferent from study participants Witll respect to their health status, it is not very likely 
that the selection was differential in the different exposure categories. Furthermore, 
ti,e response rate was relatively high (78%). 
Another cause of selection bias could be originated from the competing risk of 
coronary heart disease. The pattern of atherosclerosis follows a sequence of pro-
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gression. Plaques start to develop in the aorta, later in the coronary arteries, and 
finally in the cerebral arteries. Subjects with high cholesterol levels or high blood 
pressure may die of myocardial infarction before occurrence of stroke, which results 
in an underestimation of the strength of association hehveen cholesterol or blood 
pressure and stroke. 
Information bias 
Information bias can result from the misclassification of the disease status, of the 
determinant, and of the confounding variables. 
In our studies, like in almost all others, the level of the determinants was deter-
mined only once at baseline. Due to regression dilution bias this may dilute the asso-
ciation between typical level of the determinant and the risk of stroke. 
In our studies based on the Rotterdam Study, misclassification of the determi-
nants and confounders wcre probably not related to the future occurrence of stroke, 
and the errors were probably small since these factors were measured at baseline 
using standardised procedure. Hence the misclassification could onl)' result in a 
small underestimation of the relative risks and could hamper a bit the adequate con-
trol of confounders. 
Regarding the assessment of stroke we used state-of-the-art procedures of case 
ascertainment and standardised criteria for defining certainty of diagnosis and sub-
types of strokes. Our data showed that in most cases using all strokes or onl)' prob-
able and definite strokes made a difference only in the precision of the association 
measures) therefore we usually used all cases. One of the major limitations of our 
studies is the relatively large proportion of cases with non-specified subtypes due 
to the lack of neuro-imaging. However, the proportion of hemorrhagic stroke ,vas 
quite comparable to the findings of other studies indicating that the vast majorit)' 
of non-specified stroke cases should have been ischemic. Therefore excluding only 
hemorrhagic strokes when the relationship bctween a determinant and ischemic 
stroke was studied is justifiable. Furthermorc) exclusion of subjects with unspecified 
stroke could introduce Inore misclassification since we would have almost certainly 
excluded many ischemic stroke cases, as well. Since the reason why no neuto-imag-
ing was performed were linked to some patient characteristics (e.g. age) this would 
have resulted in selection of cases depending on the risk prome of subjects. 
Confounding 
A confounder is an alternative to causal explanation between the determinant and 
the disease. In all of our studies where we intended to quantify the relationship 
between a certain determinant and the risk of stroke ,ve adjusted for potential con-
founders. 
In some of our studies confounding by indication could playa role. In the study 
of the relationship between aspirin use and the risk of stroke we used stratification 
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for vascular disease to overcome this problem. In the study of the relationship of 
blood pressure and the risk of stroke we stratified for antihypertensive treatment to 
prevent confounding by indication. 
FUTURE RESEARCH 
Etiology of stroke 
Although our knowledge of risk factors for stroke has advanced substantially during 
the past several decades, this field will certainly develop. The list of less well-docu-
mented risk factors is quite long,' and there is no reason to assume that no new 
determinants of stroke will be identified. The field of hypercoaguability and inflam-
mation is especially promising in the near future.2-4 
Stroke is not one entity, but a group of disorders, caused by different mecha-
nisms, and it is necessary to smdy the different subtypes separately. Advances in 
neuroimaging will help classifying stroke subtypes. Understanding the differences in 
the etiology of different subtypes can help us optimising future treatment. 
Genetics of stroke is another field where progress in the future can be envis-
aged.5 Twin studies and epidemiological studies indicated that there is a genetic com-
ponent underlying the occurrence of stroke.6•7 Although research into genetics of 
strokes presents considerable challenges, advanced genetic epidemiological methods 
could pro,~de an opportunity to identify "stroke genes". Candidate gene analysis can 
be an option, but new methods of genetic linkage studies could probably mean a 
more efficient approach.s For classical genetic linkage studies it is necessary to use 
large, well-defined pedigrees with a specific stroke type. Unfortunately, since the vast 
majority of strokes occur in the elderly, it is not likely that many large pedigrees 
will be available for studies. Newer methods of linkage analysis, like affected relative 
pairs technique, seem more usefuJ.' For that large numbers of affected families arc 
needed. This underlines the necessity of international collaboration and collabora-
tion between neurologists and genetic epidemiologists. Understanding the identified 
major genes could provide new opportunities to prevent and to treat stroke. 
Research methods 
Epidemiology involves both the theory and the practice of research on occurrence 
of health related phenomena. Here, I would like to pay attention to some methodo-
logical issues that arc currently largely overlooked and can be foreseen as a field of 
improveOlent in the near future. 
An important issue is ti,e definition of ti,e determinant in etiological research. In 
many studies only dle intensity of the exposure at one point in time is used for clas-
sification, such as the baseline value of a determinant in a cohort study. I-Iowever, 
the time aspect of the exposure is clearly inlportant. With parsinlony in mind a solu-
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cion could be to use composite measure of exposure based on the time course and 
intensity of the exposure. It depends on the particular question under study whether 
tlus is appropriate or not. Using a cOlnposite measure of exposure in a situation 
\vhen there is reciprocal causation between factors, c.g. when the confounder has 
an effect on the future value of the determinants, is especially problematic. Tlus 
leads us to the more general problem of complex causal network of covariates. In 
cohort studies, where usually repeated observations arc available of determinants, 
confounders and effect, an estimation of the direct effect of a determinant is usu-
ally not straightforward. Methods to handle such causal networks in epidenliological 
research are beconling available, and will hopefully be used more extensively in the 
near future. to 
Another issue is related to measurement error. OUf analyses are based on the 
assumption that the covariates used in the analysis are measured without error. 
However, it is widely recognised that covariates are often measured with error, which 
can seriously affect the assessment of the relation between risk factors and occur-
rence of disease.!!·!2 The availability of statistical techniques to fit complex hierarclu-
cal models to deal with the problem calls for reconsidering some aspects of stndy 
design.13 In particular, we should collect information on the error in our measure-
ments. In most cases it would simply imply repeated measurements of dle covari-
ates in a small subset of study subjects. Tlus latter issue belongs to the mote general 
recognition that in some cases quantitative assessment of dle effect of biases, and 
external adjustment for them could be possible.!4 
Finally, a controversial field in epidemiology is the concept of interaction. In 
prevailing practice interaction is most widely used as a synonym for rate/odds-ratio 
modification. Tlus is simply because epidenliologic data analysis is mostly based on 
multiplicative models but has nothing to do with biologic interaction. IS Ho\'vever, 
ti,e applicability of models for biological interaction is still controversial,!6.!? It is 
important to consider effect modification in causal research, since the effect of a 
determinant can depend on the presence of anodler factor if they are complement 
causes or antagonists. 16 Our study of the effect of dietary antioxidants is an example 
of tlus. Restricting the analysis to certain suhgroups can prevent confounding and 
reduce bias, as illustrated in our analyses on the association between aspirin use and 
the risk of stroke, and between blood pressure and ti,e risk of stroke. 
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Summary 
Stroke is a common, devastating disorder. It is one of the leading causes of death and disability in developed countries. It is estimated that the preventable fraction of stroke can be as high as 80%, 
thus prevention should have a crucial role in reducing the burden stroke puts on 
societies. 
The objective of this thesis was to study some unresolved issues related to risk 
factors and prevention of stroke. 1rfost investigations were performed within the 
Rotterdam Srudy, an ongoing population based cohort srudy of elderly subjects. The 
srudy has been approved by the Medical Ethics Committee of Erasmus University / 
Academic Hospital of Rotterdam and all participants gave their informed consent. 
In chapter 2, we evaluated the performance of the Fratningham stroke risk pro-
file. Tlus profile estimates the risk of stroke and transient ischenllc attack (TIA) 
conditionally on the presence of risk factors. We found that the profile estimated 
the number of strokes and TIAs reasonably well in the different categories of the 
estimated three-year risk. The profile seemed to be a valuable tool to distinguish 
between high and low risk subjects. 
In chapter 3, we studied the relationship between blood pressure and stroke. We 
confirmed that hypertension and isolated hypertension are strong risk factors for 
stroke. W/e found a continuous increase in stroke incidence with increasing blood 
pressure in non-treated subjects. In treated subjects we found a J-shaped relation 
between blood pressure and the risk of stroke. Although tlus increased risk was 
present only under diastolic blood pressure of 65 mmHg, it may indicate that ti,e 
tllerapeutic goal "ti,e lower the better" is not the optimal strategy in the elderly. 
In chapter 4, we revisited the cholesterol paradox. This paradox refers to ti,e 
contradiction between the large beneficial effects of ti,e latest generation cholesterol 
lowering drugs, statins, in the prevention of stroke and the inconsistent findings 
of observational studies about the relationship between serum cholesterol and the 
risk of stroke. Our results showed tllat lugh serum cholesterol level significantly 
increased the risk of ischetnic stroke in subjects who were free from cardiovascular 
diseases and diabetes mellitus. We discussed possible explanations for the contro-
versy between studies. In particular, as suggested by our data, inclusion of subjects 
with changed cholesterol level secondary to cardiovascular disease could conceal the 
effect of high cholesterol on stroke. 
In chapter 5, we reported our findings about familial aggregation of stroke. His-
tory of stroke in any first degree relative increased the risk of stroke, in particular 
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for persons who had more than one relative with history of stroke or had a first 
degree relative who suffered from a stroke before the age of 65. Family history of 
early myocardial infarction also increased the risk of stroke, albeit not statistically 
significantly. Shared life-style factors and inheritance of conventional vascular risk 
factors could not explain ri,e relation between family history of stroke and risk of 
stroke. Our findings support that genetic susceptibility plays a role in the etiology of 
stroke. 
In chapter 6, we assessed ri,e potential role of dietary antioxidants in prevention 
of stroke. Higher intake of vitamin C, p~carotene, or selenium was associated with 
a lower risk of stroke in the total study population. After stratification for smoking 
behaviour it became apparent rI,at this protective effect was only present in smokers. 
Consumption of fruits and flavonoids also considerably decreased the risk of stroke 
in smokers. 
Chapter 7 describes our results about the association between aspirin use and 
the risk of stroke. Current evidence shows that aspirin can prevent stroke in patients 
after a transient ischemic attack or minor stroke. On ri,e other hand, the role of 
aspirin in primary stroke prevention is not clear. \Vie found that aspirin use was asso-
ciated with an increased risk of stroke in subjects free from vascular disease. The 
risk of ischemic stroke increased as well, albeit less than the risk of any stroke, and 
not statistically significanrly. Our finding suggest that aspirin use may increase the 
risk of stroke in elderly subjects WirllOut vascular disease. 
Chapter 8 is devoted to the efficacy and safety of carotid endarterectomy. We 
performed a meta~analysis of randomised controlled trials investigating this qlles~ 
tion. \'Ile developed a new method to handle the possibility that the effect of the 
surgical procedure was different in the different clinical trials. We found that carotid 
endarterectomy did not increase life expectancy but prolonged stroke-free survival, 
although only in high risk subjects. Our analysis supports rllat carotid endarter~ 
ectomy is useful in prevention of stroke but its application should be limited to 
patients at high risk of stroke. 
In chapter 9, we showed that the current practice of ri,e analysis of the relation~ 
ship between change in a determinant and the risk of disease may produce results. 
We illustrated the problem with an example from the Rotterdam Study and pro~ 
posed solutions. 
Although it is likely that new efficient stroke dlerapies will be developed in ri,e 
coming years, ri,e most substantial benefit in reducing the burden of stroke will 
probably come from stroke prevention. Cessation of cigarette smoking, reduction in 
heavy alcohol consumption, prOlllotion of a "healthy" diet and physical activity are 
promising tools for mass prevention. Control of hypertension and diabetes, applica~ 
tion of antiplatelet therapy, anticoagulation, and carotid endarterectomy in appro~ 
priately chosen subjects currently constitute the most valuable interventions for the 
high~risk approach of prevention of stroke. 
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Application of available means of prevention and the research focussing on find-
ing new potentially modifiable risk factors for stroke should improve our prospects 
for substantial reduction of the burden of stroke. 

Samenvatting 
B eroerte is cen veel voorkomende, invaliderende aandoening. Het is cen van de meest be!angrijke oorzaken van sterfte en blijvende invalirliteit in de Westerse landen. Naar schatting is het aandee! van beroerten dat voork6-
Inen kan worden maar Hefst 800/0. Preventie zou cen crucialc tal moeten spelen in 
de reductie van de maatschappelijke gevolgen van beroerte. 
Dit proefschrift beschrijft onderzoek naal' risicofactoren en prcventie van 
beroerte. De meeste onderzoeken werden uitgevoerd in het ERGO-onderzoek 
(Erasmus Rotterdam Gezondheid en Ouderen), een op de algemene bevolking geba-
seerd cohortonderzoek onder personen van 55 jaar en ouder. Het ERGO-onderzoek 
werd goedgekeurd door de Merlisch Ethische Conunissie van de Erasmus Univer-
siteit en het Academisch Ziekenhuis Rotterdam en alle dee!nemers gaven toestem-
tning VOOf deelname. 
In hoofdstuk 2 evalueerden we de bruikbaarheid van het risicoprofie! van de 
Framingham Studle. Dit risicoprofiel schat het fisko op beroerte van personen, con-
ditioneel op de aanwezigheid van risicofactoren. We vonden dat het aantal beroerten 
en TINs redelijk goed werd geschat in de verschillende categorieen van de geschatte 
3-jaars risico's. Het profiel bleek cen waardevol instrument om te onderscheiden 
tussen personen met laag en haag risico. 
In hoofdstuk 3 bestudeerden we de rdatie tussen bloeddruk en beroerte. Wij 
bevestigden dat hypertensie en ge1soleerde hypertensie sterke risicofactoren voor 
berocrte zi;n. Er werd cen continue verhoging van het aantal incidente beroerten 
met stijging van de bloeddruk gevonden in personen die niet behanddd werden 
voor hypertensie. In personen die wel behandeld werden vonden ,ve een J-vormige 
rdatie tussen bloeddruk en het risico op beroerte. Alhoewe! deze verhoging van 
het risico aileen aanwezig was bij een diastolisehe bloeddruk onder 65 mm Hg, sug-
gereert deze uitkomst dat het dlerapeutisehe doe! "hoe lager hoe beter" niet de opti-
male strategie is bij ouderen. 
In hoofdstuk 4 onderzoehten we de cholesterol-paradox nader. Deze paradox 
verwijst naar de tegenstelling tussen enerzijds een sterk positief effect van de laatste 
generatie cholesterolverlagende medicijnen, statines, in de preventie van beroerte 
en anderzijds inconsistente maar overwegcnd negatieve bevindingen van observa-
tionele studies naar de relatie tussen serum-cholesterol en het risico op bcroerte. 
Onze resultaten lieten zien dat een hoog serum-cholesterol gehalte het risico op een 
herseninfarct significant verhoogt in personen zonder cardiovasculaire ziekten en 
diabetes mellitus, Inaar dit effect ,vas afwezig in personen Inet preexistentc hart- en 
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vaatziekten. Een mogelijkc verklaring voor genoemde controverse tussen verschil-
lendc studies is dan oak dut inclusie van personen met hart- en vaatzickten het effect 
van hoog cholesterol op het risico op beroerte maskeert. 
In hoofdstuk 5 rapporteerden we onze resultaten over familie-aggregatie van 
berocl'te. Een voorgeschiedenis van beroertc in enig eerstegraads familielid vet-
hoogde het risico op berocrtc; in het bijzonder VOOl' pcrsonen met meet dan cen 
familielid met beroerte of een eerstegraads familielid met een beroette voor het 65e 
levensjaar. Een positieve familie-anamnese voor myocardinfarct VOO1' het 65e lcvcns-
jaar verhoogde oak het risico op beroertc, Inaar met statistisch significant. De relatic 
tussen familie-ananlnese van beroerte en het risico op beroerte kon niet worden 
verkIaard door gemeenschappelijke leefstijlfactoren of erfelijkheid van conventionele 
risicofactoren. Onze bevindingen ondersteunen de gedachte dat genetische gevoe-
ligheid een rol speelt in de etiologie van beroette. 
In hoofdstuk 6 evalueerden ,ve de 1'01 van met de voeding ingenomen antioxi-
dan ten in de preventie van beroerte. Hogere inname van vitamine C, p-caroteen of 
selenium was geassocieerd met een lager risico op beroel'te in de totale studie-popu-
latie. Na stratificatie voor roken werd het duidelijk dat dit beschermende effect aileen 
aan,vezig was bij rokers. Daarnaast zorgden consumptie van fruit en flavonoiden 
voor een aanzienlijke daling van het risico op beroerte in rokers. 
Hoofdstuk 7 beschrijft onze resultaten over de associatie tussen aspirinegebruik 
en het risico op een beroerte. Aangen01nen wordt dat aspidne beroerte kan voork6-
tnen na een TIA of 'minor stroke. De 1'01 van aspirine in de primaire preventie 
van beroerte is echter niet duidelijk. We vonden dat aspirine geassocieerd was met 
het risico op beroerte in persanen zander vasculaire ziekten. Het risico op hersen-
infarcten was ook verhoogd, maar mindel' dan het risico op aile beroerten, en niet 
statistiscb significant. Onze resultaten suggereren dat el' geen 1'01 is voor aspirine in 
de pl'imaire preventie van beroerte in personen zonder vasculaire ziekten. 
Hoofdstuk 8 is gewijd aan de effectiviteit en veilighcid van carotis endarteriec-
tomie. Wle voerden een meta-analyse nit van gerandomiseerde klinische trials die 
deze vraag onderzochten. We ontwikkelden een nieuwe methode om rekening te 
houden met de mogelijkIleid dat het effect van de chirurgische procedure verschil-
lend was in de verschillende trials. \YJe vonden dat carotis endarteriectomie nuttig is 
in de preventie van beroerte, maar dat de toepassing zou moeten ,varden beperkt tot 
patienten met cen haag risico op beroerte. 
In hoofdstuk 9 toonden we aan dat de huidige praktijk van analyse van de relatie 
tussen verandering in een determinant en bet risico van ziekte crnstig vertekende 
resultaten kan opleveren. We illustreerden het probleem met een voorbecld uit het 
ERGO-onderzoek en stelden oplossingen voor. 
Alhoewel bet aannemelijk is dat er in de komende jaren nieuwe therapieen voor 
beroerte zullen worden ontwikkeld, is de Incest substanticle wmst in de reductie van 
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de maatschappelijke gevolgen van beroerte te behalen door preventie. Stoppen met 
roken, reductie van zwaar alcoholgebruik, bevorderlng van een gezond clieet en licha-
tnelijke activiteit zijn de veelbelovende instrumenten voor massa-preventie. Controle 
van hypertensie en diabetes, toepassing van plaatjesaggregatie-rellllllers, antistolling 
en carotis endartericctomie in de juiste personen vormen de meest waardevolle 
interventies voor de hoog risico-benadering van de preventie van beroerte. 
Toepassing van beschikbare methoden van preventie en onderzoek naar nieuwe 
preventiemogelijkheden zullen onze uitzichten op een substantiele reductic van de 
lllaatschappelijke gevolgen van beroerte verbeteren. 

OsszefoglaUis 
A stroke (szeliites, agyi erkatasztr6fa) gyakori, igen sulyos betegseg. A fejlett tarsadalmakban az egyik vezeto halalok, es a rokkantsagnak is az egyik leggyakoribb oka. 
Becslesek szerint a stroke-ok akar 80%-a is megel6zhet6lenne, igy a megel6zesnek 
rendkiviil nagy szerepe van abban, hogy az agyerbetegsegek miatt a tarsadalomra 
nehezed6 terhek cs6kkenthet6k legyenek. 
Ennek a tezisnek a eelja az volt, hogy a stroke kockazati tenyez6ivel es 
megel6zesevel kapcsolatos megoldatlan kerdeseket kutassa. A legt6bb vizsgalatra a 
Rotterdam Vizsgalat -folyamatban lev6, id6sek k6reben zaj16 populaci6s kohorsz 
vizsgalat - kereteben keriilt sor. A vizsgalatot az Erasmus Egyetem es a Rotterdami 
Egyetemi K6rllaz Etikai Bizottsaga engedelyezte. 
A 2. fejezetben ertekeltiik a framinghami stroke kockazati fiiggvenyt. A 
fiiggveny a kockazati tenyez6k meglete alapjan becsli a stroke kockazatat. A 
fiiggveny elfogadhat6an becsiilte a stroke-ok es az atrncneti agyi ischaemias 
t6rtenesek erIA) szamat a becsiilt Ilaromeves kockazat kiil6nb6z6 kateg6riaiban. 
A fiiggveny hasznos eszk6znek bizonyult a kii16nb6z6 kockazattal bir6 szemelyek 
megkii16nb6zteteseben. 
A 3. fejezetben a vemyomas es a stroke k6z6tti kapcsolatot vizsgaltuk. 
Vizsgalatunk tneger6sftette, hogy a tnagas vernyomas e.s az izohUt szisztoles tnagas 
vernyomas a stroke jclcntos kockazati tenyez6je. Azt tahl.ltuk, hogy vernyomas 
csokkent6 kezeU:sben nem reszesUl6 szemelyekben a stroke kockazata folyamatosan 
emelkeclik a vemyomas emelkedeseve!. Kezelt szemelyekben J-alaku kapcsolatot 
talaltunk a vernyomas os a stroke kockazata k6z6tt. Bar emelkedett kockazat csak 65 
Hgtntn-es cliasztoU:s vernyomas alatt volt megfigyelheto, ez jelezheti, hogy a "minei 
alacsanyabb, annal jobb" strategia nem feltetleniil optimalis id6sekben. 
A 4. fejezetben {Ijra megvizsgaltuk a koleszterin paradoxont. A paradoxan a 
legujabb koleszterincs6kkent6 gy6gyszereknek, a statinoknak, a stroke megel6zesben 
kitllutatott igen kedvez6 hatasa e.s a megfigyclcses vizsgalatok inkonzisztens 
eredmenyei k6z6tti ellenunondasra uta!' Az eredmenyeink azt mutattak, hogy 
a keringesi betegscgekt6l cs a cukorbetegsegt6l mentes szemelyekben a magas 
koleszterln szint szignifikansan novelte az agyi ischacmhl.s infarktus kockazatat. 
Ismertettiik a korabbi vizsgalatok eredmenyeivel kapcsolatos legfontosabb 
megfontolasokat. A mi vizsgaIatunk azt mutatta, hogy a keringesi betegsegek meglcte 
elfedheti a magas koleszterin szintnek a stroke kialakulasaban bet6lt6tt szerepet. 
Az 5. fejezetben k6z6ltiik a stroke csalacli halmoz6dasaval kapcsolatos 
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eredmenyeinket. Emelkedctt a stroke kockazata azon szemelyeknel, akik elsOfokll 
rokonai koreben el6fordult stroke. Kiilonosen emelkedett a stroke kockazata, ha 
valakinek t6bb ilyen rokona volt, vagy a rokon 65 eves kora elott szenveclett stroke-at. 
Korai szfvinfarktus a csaladi anamnezlsben szinten mcgnovelte a stroke kockuzatat, 
bar statisztikailag nem szignifikansan. A kozos eletm6dbeli tenyez6k es a stroke 
hagyomanyos kocblzati tenyezoinek oroklese nem magyaraztak a kapcsolatot a 
pozitiv csaladi anamnezis e.s a stroke k620tt. Az eredmenyeink ana utalnak, hogy a 
genetikai fogekonysag szerepet jatszik a stroke etiol6giajaban. 
A 6. fejezetben az etrendi antioxidansok es a stroke kapcsolatat vizsgaltuk. 
Nagy tnennyisegu C-vitamin, p-carotin vagy szeleruum bevitele csokkentettc a 
stroke kockazatat. A d:tegzett elemzes azt mutatta, hogy a kedvez6 hatas csak 
dohanyosokban van jelen. A gyiimolcs es flavonoid fogyasztas szinten jelent6sen 
csokkentette a stroke kockazatat a dohanyosokban. 
j\ 7. fejezet az aszpirin fogyasztas es a stroke osszefiiggesevel kapcsolatos 
eredmenyeinket frja Ie. A rendelkezesre aIl6 bizonyftekok azt mutatjak, hogy atmeneti 
agyi ischaemias tortenest, vag)' enyhc stroke-at szenvedett betegek k6rcben az 
aszpirin kedvezo hatasu a stroke megelozeseben. Ugyanakkor nem vllago~ aZ aszpirin 
szerepe a stroke primer prevenci6jaban. Azt taIaltuk, hogy erbetegsegt61 mentes 
szemelyek koreben az aszpirin fogyasztlls emelkedett stroke kockazattal jar. 1\z 
ischaemias agyi infarktus kocbizata szinten emelkedett, bar kisebb es statisztikailag 
nem szignifikans mertckben. Eredmenyeink arra utalnak, hogy az aszpirin emelheti 
a stroke kockazatat erbetegsegt6lmentes id6sek koreben. 
A 8. fejezetet a carotis endarterectomia hatekonysaganak es biztonsaganak 
szenteltiik. A kerdest vizsgat6 randomizaIt klinikai vizsgalatok meta-analiziset 
vegeztiik el. Egy uj m6dszert fejlesztettiink ki, amely kepes figyelembe venni, 
hogy a beavatkozas hatekonysaga a killonboz6 vizsgalatokban kiilonb6zo volt. 
Azt tahUhlk, hogy a carotis cndarterectomia nein noveli a varhat6 eiettartamot, 
de magas kockazarn egyenekben megnoveli a stroke nelkiil varhat6 eIettartamot. 
Az eredmenyeink azt mutatatjak, hogy a carotis cndarterectoluia hasznos eszkoz a 
stroke megel6zeseben, de az alkahnazasat a magas kockazatll egyenek k6rerc kell 
korlatozni. 
A 9. fejezetben megmutattuk, hogy a jelenleg elterjedt m6dszer, amellyel egy 
kockazati tenyez6 valtozasa es egy betegseg kockazata kozti osszefiiggest vizsgahli 
szoktak nagymertekben torzftott eredmenyhez vezethet. A problemat iIIusztraltuk, 
egy, a Rotterdam vizsgalatb61 vett peIdaval, es javasoltunk megoldasokat. 
Ugyan val6szfnu, hogy a stroke-nak uj, hatekony terapiait fogjak kifejleszteni az 
elkovetkez6 evekben, a legnagyobb csokkenes a stroke jelentette terhekben megis 
velhet6en a megel6zesb6l fog szarmazni. A dohanyzas elhagyasa, a nagymerteku 
alkoholfogyasztas csokkentese, az "egeszscges" ctkezesi szokasok es a testmozgas 
terjedese fgeretes eszkozok az egesz populaci6t megcelz6 megel6zesben. A magas 
vcrnyomas es a cukorbetegseg kezelese, az antiaggrcgaci6s es antikoagulans kezeles 
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es a carotis endarterectomia a legertekesebb eszkazak a megfeleloen kivalasztott 
magas kocblzatu szemelyek koreben a stroke megelozesere. 
A megelozes rendelkezesre aU6 eszkazeinek alkalmazasa es az ujak utani kutatas 
rcmelhet61eg jelentos mertekben csakkenteni fogjak a stroke jelentette tarsadalmi 
terheket. 
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